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Abstract 
 
Over recent years the delivery of nanosized drug particles has shown potential in 
improving bioavailability. Drug nanosizing is achieved by “top-down” and by “bottom-
up” approaches. Owing to limitations associated with the top-down techniques, such as 
high energy input, electrostatic effects, broad particle size distributions and 
contamination issues, great interest has been directed to alternative bottom up 
technologies. 
In this study, the hypothesis that microreactors can be used as a simple and cost-
effective technique to generate organic nanosized products is tested using three steroids 
(hydrocortisone, prednisolone and budesonide). Arrested antisolvent nanoprecipitation 
using ethanol (solvent) and water (antisolvent) was conducted within the microreactors. 
To enable experimental design for the microreactor studies, solubility profiles in 
different ethanol-water combinations at 25 °C were explored. All three drugs’ solubility 
increased with increasing ethanol concentration showing maxima at 80-90 % v/v 
ethanol-water mixtures. Because of the complex multivariate microfluidic process, 
artificial neural network modelling was then employed to identify the dominant 
relationships between the variables affecting nanoprecipitation (as inputs) and the drug 
particle size (as output). The antisolvent flow rate was found to have the major role in 
directing drug particle size. 
Based on these successful findings, the potential of preparing pharmaceutical 
nanosuspensions using microfluidic reactors was researched. A hydrocortisone (HC) 
nanosuspension (NS) was prepared by introducing the generated drug particles into an 
aqueous solution of stabilizers stirred at high speed with a propeller mixer. A tangential 
flow filtration system was then used to concentrate the prepared NS. Results showed 
that a stable narrow sized HC NS of amorphous spherical particles 500 ± 64 nm 
diameter and zeta potential −18 ± 2.84 mV could be produced.  
The ocular bioavailability of a microfluidic precipitated HC NS (300 nm) was 
assessed and compared to a similar sized, milled HC NS and HC solution as a control. 
The precipitated and the milled NS achieved comparable AUC0-9h of 28.06 ± 4.08 and 
30.95 ± 2.2, respectively, significantly (P < 0.01) higher than HC solution (15.86 ± 2.7). 
These results illustrate the opportunity to design sustained release ophthalmic 
formulations.   
Going nano via microfluidic precipitation was also exploited to tailor 
budesonide (BD) NS for pulmonary administration. The in vitro aerosolization by 
nebulization of a BD NS was studied in comparison with a commercial BD 
microsuspension. Overall, the fine particle fraction generated from BD NS (56.88 ± 
3.37) was significantly (P < 0.05) higher than the marketed BD (38.04 ± 7.81). The 
mean mass aerodynamic diameter of BD NS aerosol (3.9 ± 0.48 µm) was significantly 
smaller (P < 0.05) than the microsuspension (6.2 ± 1.09 µm) indicating improved 
performance for BD NS. 
In conclusion, findings of this study support the hypothesis of using microfluidic 
nanoprecipitation as a promising and economical technique of drug nanosizing.  
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HGCP High gravity reactive precipitation 
HGRP High gravity reactive precipitation 
HPH High pressure homogenization 
HPLC High performance liquid chromatography 
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HPMC Hydroxypropylmethylcellulose 
IOP Intraocular pressure 
M Molar 
MMAD Mean median aerodynamic diameter 
mg Milligram 
min Minute 
ml Milliliter 
mm  Millimeter 
mmol Millimolar 
MRT Mean residence time 
mp Melting point 
ND Nanodispersion 
nm Nanometer 
NS Nanosuspension 
PCS Photon correlation spectroscopy 
PI Polydispersity index 
PVP Polyvinylpyrrolidone 
PXRD Powder X-Ray diffraction 
RESS Rapid expansion from supercritical fluids 
s Second 
SAS Supercritical anti-solvent precipitation 
SCF Super critical fluid 
SD Spray-dried / Standard deviation 
SFL Spray freezing into liquid  
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SDS Sodium dodecyl sulfate 
SEM Scanning electron microscopy 
TEM Transmission electron microscope 
TFF Tangential flow filtration 
tmax Time for maximum responce 
vs. Versus 
H2O Water 
w/v weight/volume 
w/w weight/weight 
v/v volume/volume 
μl Microliter 
μm Micrometer 
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1.1 Nanotechnology and drug delivery 
 
1.1.1 Introduction 
 
 
It is expected that the near future will embrace the era of nanotechnology 
(nano = dwarf in Greek).  Nanotechnology is attracting more interest as an important 
and promising field because of its potential applications ranging from biotechnology, 
electronics, medicines and cosmetics.  Nanotechnology spans many fields including 
engineering, electronics, physical, material science and manufacturing at a molecular 
or submicron level (Sahoo 2008; Araújo et al. 2009).  
 
The terms “nanotechnologies” and “nanoscience” have been defined by the 
Royal Society and Royal Academy of Engineering (Pitkethly 2004; Borm et al. 2006) as 
follows: 
 
• “Nanotechnologies are the design, characterization, production and application 
of structures, devices and systems by controlling shape and size at nanometer 
scale”. 
• “Nanoscience is the study of phenomena and manipulation of materials at 
atomic, molecular and macromolecular scales, where the properties differ 
significantly from those at a larger scale”.  
 
Applying nanotechnology to medicine is referred as “nanomedicine” or 
“nanobiomedicine” and covers the monitoring and treatment of diseases as well as the 
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control and understanding of biological systems (Khademhosseini and Langer 2006). 
Moreover, nanotechnology contributes in improving the conventional techniques of 
diagnosis in clinical laboratories. It permits testing of small sample volumes, detection 
of a few micro-organisms or molecules and allows early discovery of diseases and thus 
improves the chance of treatment (Jain 2005). Despite still being an emerging 
technology, it is reported that more than 1000 nano-pharmaceutical patents have 
been issued by the U.S. Patent and Trademark Office (U.S. PTO) during the period 1999 
– 2008 (Mishra et al. 2010). 
 
1.1.2  Nanoparticulate drug delivery systems 
 
 
In pharmaceutical research, it is widely accepted to define nanoparticles as 
colloidal-sized particles possessing diameters between 1 and 1000 nm (Letchford and 
Burt 2007). Although some definitions are more restrictive and focus on sizes below 
100 nm (Lavan et al. 2003; Reverchon and Adami 2006), the 100 nm limit is 
constraining and many recent discoveries would have been missed (Rogueda and 
Traini 2007). 
 
Drugs can be loaded into nanoformulations in different ways (Figure 1-1), and 
accordingly different terms can used to describe these systems. Nanocapsules are tiny 
vesicles in which the drug is entrapped within a cavity surrounded by a polymer 
membrane (Mishra et al. 2010), while nanospheres involve systems in which the drug 
is physically and uniformly dispersed in a matrix (Soppimath et al. 2001).  
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Drug nanocrystals are nanoparticles composed of 100 % of drug crystals 
without any matrix materials. According to methods of preparation, amorphous or 
crystalline drug nano-sized particles can be obtained. Other examples of 
nanoparticulate drug delivery systems are shown in Figure 1-1 (Faraji and Wipf 2009):  
 
• Liposomes: spherical vesicular concentric bi-layered structures 
composed of an inner core that is surrounded by one or more 
phospholipids bi-layers. 
• Micelles: aggregates of amphiphilic molecules (surfactants) in a 
dispersion medium. 
• Solid lipid nanoparticles: lipid-based submicron aggregates. They have 
rigid cores consisting of hydrophobic lipids that are solid at room and 
body temperatures, surrounded by a monolayer of phospholipids.  
• Nanotubes: self-assembling sheets of atoms arranged in tubes. These 
tubes may be organic or inorganic in composition and can be obtained 
as single- or multi-walled structures. 
• Dendrimers: spheroid, highly branched, polymer-based macromolecules 
built from monomeric or oligomeric units. They consist of 3 components 
core, branches and end groups. 
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Figure 1-1: Different nanoparticulate drug delivery systems. 
 
Source (Faraji and Wipf 2009). 
 
 
 
1.1.3 Approaches for drug nanosizing 
 
 
The process of reducing drug particle size below the 1-micron level has been 
referred to as drug nanosizing (Filippos Kesisoglou et al. 2007). The term nanonization 
has also been used to describe this process (Jia et al. 2002; Moschwitzer and Muller 
2006; Dhumal et al. 2008; Chen et al. 2010). Several production techniques have been 
reported in the literature to achieve the nano-state for drug particles. These 
techniques can be categorised into two main approaches, “top-down” and “bottom-up 
technologies” and/or their combination (Figure 1-2).  
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Figure 1-2: Approaches of drug nanonization. 
 
1.1.3.1 Top-down approach 
 
 
The top-down technologies involve mechanical attrition of larger drug particles. 
Out of these technologies, media milling (e.g. NanoCrystal® (Elan Drug Technology)) 
and high-pressure homogenization (e.g. Disso Cubes® (Skyephrma)) have been 
successfully employed in preparing commercialized drug nanoparticles (Hu et al. 
2008).  
 
In media milling (Figure 1-3), the micron sized drug particles is reduced to 
nanoparticles in the presence of grinding media and surface stabilizers. The grinding 
media can be made of glass, zirconium oxide, ceramics, stainless steel or polystyrene 
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resins (Van Eerdenbrugh et al. 2008). The surface stabilizers include various polymers 
(e.g. cellulose derivatives, polyvinylpyrrolidone) and / or surfactants (e.g. sodium lauryl 
sulfate, polaxamer). Media milling has been employed in nanosizing of naproxen 
(Liversidge and Conzentino 1995), danazol (Liversidge and Cundy 1995), a poorly 
water-soluble drug / carrageenan complex (Dai et al. 2007) and itraconazole (Yang et 
al. 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3: Diagram illustrates an example of a media milling process. 
 
Source (Merisko-Liversidge et al. 2003) 
 
 
 High pressure homogenization is another top-down method that is commonly 
employed in drug nanosizing. Two types of homogenizers have been successfully used 
to prepare drug nanoparticles; microfluidizers and piston-gap homogenizers. In 
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microfluidization, the drug suspension is sprayed at high velocity into specially 
designed homogenization chamber, where, the direction of suspension stream flow 
changes leading to particle collision and shear forces (Ganta 2008). Alternatively, in 
piston-gap homogenizers, the drug suspension containing stabilizers is passed through 
the narrow gap of a homogenizer at high pressure (Figure 1-4). This pressure creates 
sufficient powerful disruptive forces (cavitation, collision and shearing) able to 
disintegrate coarse particles into nanoparticles (Junghanns and Muller 2008; Chen et 
al. 2010). The overall size of the produced particles is affected by the number of cycles 
and the homogenizing pressure. Smaller nanocrystals can be generated by increasing 
the homogenization pressure and the number of homogenization cycles (Hecq 2006). 
Examples of drugs that had been successfully nanonized by high pressure 
homogenization include nifedipine (Hecq et al. 2005), hesperetin (Mishra et al. 2009), 
asulacrine, a drug with a potential against breast and lung cancer (Ganta et al. 2009), 
amphotericin B (Kayser et al. 2003) and omeprazole (Möschwitzer et al. 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-4: Schematic representation of a high-pressure homogenization process. 
 
Source (Junghanns and Muller 2008).  
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1.1.3.2 Bottom-up approach 
 
 
In “bottom-up” technologies, drug nanoparticles are formed from drug 
molecular solutions by rapid solvent removal or precipitation by adding the solution to 
an antisolvent. The following paragraphs illustrate some of these technologies. 
 
Supercritical fluids (SCF) involve gases and liquids at temperatures and 
pressures higher than their critical points. In Figure 1-5, the critical point exists at the 
upper end of the liquid: gas-vapour pressure curve, while the phase area in beyond 
this point is known as the SCF region (York 1999). Supercritical CO2 is commonly used 
due to its acceptable properties [low critical temperature (31.1°C), non-flammable, 
non-toxic, inexpensive] (Palakodaty and York 1999).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5: The phase diagram of a pure compound. 
 
 Source (York 1999). 
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Several SCF particle engineering technologies has been used to prepare drug 
micro and nanoparticles. The SCF can act as a solvent or as an anti-solvent for the 
precipitation of drug material (Yasuji et al. 2008). In the rapid expansion from 
supercritical fluids (RESS) process (Figure 1-6, A), the drug is first extracted and 
dissolved into an SCF followed by depressurization through spraying into a collection 
chamber. As a result of rapid expansion, drug supersaturation, nucleation and 
subsequent precipitation in the form of narrow-sized small particles occurs (Jung and 
Perrut 2001). Cefuroxime axetil nanoparticles sized between 158-513 nm (Varshosaz et 
al. 2009) and digitoxin nanoparticles of 68–458 nm (Atila et al. 2010) were produced 
using RESS. A modified type of the RESS process, the rapid expansion of supercritical 
solution into a liquid solvent (RESOLV) (Figure 1-6, C), involves spraying the 
supercritical solution into a liquid (which may contain stabilizers) in order to minimize 
the particle aggregation during expansion (Byrappa et al. 2008). RESOLV has been used 
to nanosize ibuprofen particles in aqueous suspension (Pathak et al. 2006) and also to 
produce poly-l-lactide nanoparticles loaded with retinyl palmitate (Sane and Limtrakul 
2009). 
 
In supercritical anti-solvent (SAS) methods (Figure 1-6, B), the sprayed SCF acts 
as an antisolvent for the drug that initially dissolved in organic solvent. SCF diminishes 
the solvent strength, providing a good SCF/solvent solubility, leading to precipitation of 
the drug. Among the reported studies in the scientific literature, griseofulvin 
nanoparticles (Chattopadhyay and Gupta 2001), lysosyme nanoparticles (Fusaro et al. 
2009) and atorvastatin calcium nanoparticles (Kim et al. 2008) were successfully 
prepared using the supercritical antisolvent (SAS) process. 
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Figure 1-6: Particle engineering by different CSF technologies.  
(A: RESS,   B: SAS,   C: RESOLV).    
 
Source A, B (Mishra et al. 2010),    C (Sane and Limtrakul 2009). 
 
A 
C 
B 
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High gravity controlled precipitation (HGCP) has been employed recently to 
synthesize nanoparticles.  HGCP involves two operation modes; high gravity reactive 
precipitation (HGRP) and high gravity antisolvent precipitation (HGAP) (Hu et al. 2008 
A). HGRP method generates nanoparticles through micromixing of reactants at high 
gravity with the help of rotating packed bed (RPB) (Figure 1-7).  The mass and heat 
transfer between the reactants is markedly enhanced by high gravity micromixing 
favouring rapid and homogenous drug nucleation and crystal growth suppression 
(Date and Patravale 2004). When the reactants enter the rotating packed bed under 
the high shear created by the high gravity, they are split into very thin films or 
nanodroplets. Micromixing together with the centrifugal force intensify mass transfer 
resulting in nanoparticles formation (Date and Patravale 2004). The feasibility of 
producing organic nanoparticles of benzoic acid as a model compound using HGRP 
technique has been studied (Chen et al. 2004). Zhong et al. (2005) combined the 
reactive precipitation and anti-solvent precipitation to prepare nanosized particles of 
cephradine (200–400 nm) with narrow particle size distribution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 1-7: A diagram represents the HGCP process. 
  
 Source (Hu et al. 2008 B). 
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The evaporative precipitation into aqueous solution (EPAS) technique (Figure 
1-8) is reported to produce drug particles of submicron to micron size stabilized by 
surfactants or polymers dispersed in an aqueous medium (Sinswat et al. 2005). The 
drug is first dissolved in an organic solvent, then pressurized, heated and sprayed with 
an atomizer into a heated aqueous solution containing stabilizer(s). An intense 
atomization is created due to the large pressure drop across the small nozzle orifice. 
The primary organic solvent evaporates rapidly because of the high temperature of the 
feed solution and aqueous receiving solution (Vaughn et al. 2006). Rapid evaporation 
of the small organic droplets generates a high degree of drug supersaturation and 
rapid nucleation. The stabilizer(s) in water can be adsorbed to the surfaces of drug 
particles and thus prevents particle growth, agglomeration or crystallization (Chen et 
al. 2004). EPAS was successfully applied to prepare nanosuspensions of amorphous 
cyclosporine (Chen et al. 2002). 
 
 
 
Figure 1-8: Schematic of EPAS process and intense atomization of the spray. 
 
 Source (Sinswat et al. 2005). 
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Spray freezing into liquid (SFL) (Figure 1-9) is a cryogenic particle engineering 
process that utilizes atomization of a feed solution containing drug and/or excipient(s) 
directly into a cryogenic liquid to produce frozen nanostructured particles. The 
particles produced are then lyophilized to obtain dry and free flowing powders (Hu et 
al. 2003). A rapid dissolving danazol powder containing amorphous nanostructured 
aggregates with high surface area and excellent wettability has been produced using 
SFL (Hu et al. 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-9: Diagram of the SFL process. 
 
 [The solution cell (A), high pressure pump (B), atomizing nozzle (C), and the cryogenic 
liquid cell (D)]. 
 
Source (Hu et al. 2003). 
 
1.1.3.3 Combination technologies 
 
 
In combination technologies, the drug particles could be initially precipitated 
then subjected to homogenization (e.g. NanoEdge™ Technologies (Baxter Baxter 
Healthcare Corporation). As a result, the drug particle size can be kept at a nano- size 
relative to the growing particles obtained after the precipitation step. Moreover, the 
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precipitated drug particles can be converted to a more stable crystalline compound 
due to this annealing process (Keck and Müller 2006). A combination of 
microprecipitation and high-pressure homogenization techniques has been employed 
to obtain uniform nanosuspensions with mean diameter of 131 nm of 10-
hydroxycamptothecin (a drug with promising and potent anti-tumor activity) (Pu et al. 
2009).   
 
1.1.3.4 Comparison of drug nanosizing approaches 
 
The relative advantages/disadvantages of drug nanosizing techniques are 
shown in Table 1-I.  
Table 1-I: Advantages and disadvantages of different techniques of drug 
nanonization. 
 
 (Junghanns and Muller 2008). 
Technology Advantages Disadvantages 
Top down 
Milling 
- Proven by 4 FDA approved 
drugs. 
- Possible contaminations  
from milling media. 
- Long processing time. 
- Needs to be stabilized 
- Limited size of milling 
chamber (difficult to process 
large batches). 
 
Homogenization 
- Universal applicability. 
- Large batches can be 
processed. 
- Relatively fast method. 
- High energy technique. 
- Great experience is needed. 
 
Bottom up Precipitation 
- Finely dispersed drug. 
-Good control of desired 
size. 
 
-Certain conditions of 
pressure and temperature 
may be needed as in CSF. 
- Needs to be stabilized. 
- Organic solvent residue. 
- Drugs solubility is required. 
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1.1.4 Going nano: benefits for drugs 
 
 
Generally speaking, novel and unusual properties (mechanical, chemical, 
physical, thermal, electrical, optical, magnetic or biological properties) can be achieved 
by putting materials at the nanodimension scale (Byrappa et al. 2008). The unique 
characteristics of nanosized materials result from their nanometer-scale structure size, 
structure-dependent electronic configurations and the high surface-to-volume ratio 
compared to bulk materials (Oberdorster et al. 2005 B). Such properties make nano-
materials attractive for medical development and industrial application. For example, 
when put in a nanostate, it is possible to develop explosives, colouring matters, toners, 
polymers, biopolymers, metals, metal oxides with improved functional and structural 
properties (Reverchon and Adami 2006; Reverchon et al. 2007).   
 
Moving to the pharmaceutical field, drug nanonization also offers important 
advantages. At the nanodimensions, compounds having similar chemical and structural 
composition but with no or low therapeutic values in their bulk sized forms may be 
transformed into compounds of enhanced therapeutic activity. Nanoparticles of silver 
and gold are more reactive, unlike their large particles counterparts. They possess 
antimicrobial properties, which help in to prevent infection and wound healing (Chan 
2006). Some of the advantages gained by drug nanonization can be explained in the 
following sections: 
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1.1.4.1 Increased surface area and surface to volume ratio 
 
 
Through drug particle size reduction down to the micron level and further 
down to nano-level, the specific surface area (the surface area divided per unit mass or 
volume) is further and further increased. As reported, after danazol nanonization from 
55 µ m (of the raw danazol) to 364 nm, a 21-fold increase of the specific surface area 
from 0.66 to 14.37m2/g respectively occurred (Zhao et al. 2007). Also, the specific 
surface area of itraconazole nanoparticles (D50=230 nm) was 71.48 m
2/g, in contrast to 
2.20 m2/g for the unprocessed bulk itraconazole and 1.80 m2/g for a physical mixture 
(itraconazole: mannitol: lecithin in the weight ratio of 1:0.5:0.2) (Yang et al. 2008). 
 
Furthermore, with particle size reduction, greater proportions of atoms or 
molecules can be oriented on the surface rather than within the interior of substances 
(higher surface-volume ratio). To illustrate, a particle of size 30 nm has 5% of its atoms 
on its surface, at 10 nm 20% of its atoms, and at 3 nm 50% of its atoms (Pison et al. 
2006).  Figure 1-10 illustrates how the ratio of surface to total atoms or molecules 
increases exponentially with decreasing particle size. Accordingly, the surface area per 
unit mass possessed by nanoparticles is much larger relative to macro-sized particles. 
The increase in the surface to volume ratio will increase the particle surface energy 
and may render them more biologically reactive (Oberdorster et al. 2005 B). 
Enhancement of biological activity may be desired (e.g. activity as antioxidant) or 
undesired (e.g. increased toxicity or induction of oxidative stress) (Oberdorster et al. 
2005 A).  
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Figure 1-10: Surface molecules as a function of particle size.  
 Source (Oberdorster et al. 2005 A). 
 
 
1.1.4.2 Increased saturation solubility 
 
 
Formulation of poor water-soluble drugs is a challenging problem facing 
researchers in the pharmaceutical field. According to the literature, it is currently 
estimated that approximately 50% of developed compounds, and this is expected to 
rise in the future, in the pharmaceutical field are of poor aqueous solubility (Mauludin 
et al. 2009 A). This could be due to the new paradigm in high – throughput screening 
of developed drug candidates, which emphasizes the importance of good fit with 
target-receptor geometry. Candidates resulting from such screens have high molecular 
mass and high log P, both of which are contributing factors of poor solubility (Rabinow 
2004). The clinical utility of poorly soluble compounds, especially for class II— high 
permeability, low solubility compounds (The Biopharmaceutics Classification System, 
BCS) may be greatly affected due to their low solubility profile (Faller and Ertl 2007).   
 
Several strategies can be employed, with reasonable success, to modify the 
solubility behavior of poorly soluble drugs. These methods involve the usage of 
surfactants, complexing agents, co-solvents or through modifying the drug itself (salt 
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formation or prodrugs). However, these methods may have a limited utility. For 
example, to suit these methods, drugs should possess certain features (e.g. contains 
ionizable group for salt formation, soluble in certain organic solvents or of suitable 
molecular conformation to be associated with (such as to fit within cyclodextrins 
cavity)). Furthermore, the possible toxicity associated with the use of solubility 
enhancers should be considered. For example cremophor EL increases the toxicity of 
taxol and HP-ß-cyclodextrin is reported to cause nephrotoxicity of the Sporanox® 
formulation of itraconazole (Willems et al. 2001). Organic solvent residues may add 
other disadvantages. Accordingly, a universal solubilization approach is strongly 
demanded. 
 
Drug particle size diminution (e.g. micronization) can be also applied to 
increase solubility characteristics and bioavailability of drugs with low aqueous 
solubility. However, many compounds still show a low solubility even after 
micronization as such size reduction improves the drug dissolution rate mainly by 
increasing surface area and not by increasing the saturation solubility (Muller 2001; 
Ravichandran 2009). The consequent step, i.e., drug nanonization, may breathe a new 
life into poorly soluble drugs through increasing their saturation solubility. 
Furthermore, this approach has a universal applicability to process any insoluble drug, 
particularly, for drugs being poorly soluble in both aqueous and organic media 
(Sigfridsson et al. 2009). 
 
The term saturation solubility is commonly used in the literature to express the 
equilibrium solubility of drug nanoparticles (see section 2.1). The influence of drug 
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where: 
S    : saturation solubility of the nanosized   
         drug.  
S∞  : saturation solubility of an infinitely   
         large drug crystal. 
γ    : the crystal-medium interfacial tension. 
M  : the compound molecular weight. 
r   : the particle radius.  
ρ   : the density of drug particles. 
R   : the gas constant.  
T   : the absolute temperature.  
 
nanonization on saturation solubility can be explained by the Kelvin equation (see 
equation 1) which describes the vapour pressure as a function of curvature of liquid 
droplets (Böhm and Müller 1999):  
 
  
     𝑳𝒏
𝑷𝒓
𝑷∞
 = 
𝟐𝜸𝑴𝒓
𝒓 𝑹𝑻𝝆        Equation 1 
 
 
As a result of their high curvature, very small liquid droplets show an increased 
vapour pressure with the accelerated possibility of drug molecules escaping from the 
liquid phase of the droplet to the gas phase (Keck and Muller 2006). Similarly, by 
applying this concept to the drug dissolution process, (i.e., the solid–liquid interface) 
the dissolution pressure could replace the vapour pressure in the Kelvin equation. 
According to this equation, size reduction leads to an increase in the dissolution 
pressure (Junghanns and Muller 2008). 
 
Ostwald–Freundlich equation (see equation 2) can also help to explain the 
increased saturation solubility with particle size reduction (Kesisoglou et al. 2007): 
 
   
  𝑺 = 𝑺∞ 𝒆𝒙𝒑( 𝟐𝜸𝑴𝒓𝝆𝑹𝑻)   Equation 2  
 
  
where: 
Pr   :  the vapour pressure of a particle  
           with the radius r.  
P∞ : the vapour pressure of an infinitely  
         large particle.  
γ    : the surface tension. 
R   : the gas constant. 
T   : the absolute temperature. 
r    : the radius of the particle.  
Mr : the molecular weight. 
ρ    : the density of the particle.  
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From the Ostwald–Freundlich equation, it can be concluded that a drug shows 
a higher solubility when the particle radius is decreased. This effect is not substantial 
for larger particles, but is more pronounced for particles below 1 µm (Muller 2001). 
 
Muller and Peters (1998) reported that the saturation solubility of RMKP 22 (a 
model hydrophobic drug) approximately doubled when entering the nanometer range 
(from particle size of 2.4 μm to 300 nm).  Figure 1-11 shows the solubility of asulacrine 
(a poor water soluble compound with potential activity against breast and lung cancer) 
as a function of particle size. Upon decreasing drug particle size, as a result of 
successive size-reduction steps, the solubility increased, with the highest solubility 
achieved with a particle size of 133 nm (Ganta et al. 2009). An increase in saturation 
solubility was also found after formulating PX-18 (a new highly potent phospholipase 
A2 inhibitor with poor aqueous solubility) as nanosuspensions compared to bulk 
material (Pardeike and Müller 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-11: Solubility as a function of particle size following successive size-
reduction steps for asulacrine. 
 
Source  (Ganta et al. 2009). 
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1.1.4.3 Increase of dissolution rate 
 
 
The drug dissolution process can be described by the Noyes-Whitney equation 
(3).  
 
    
𝒅𝑪
𝒅𝒕
 = 𝑫𝑨 (𝑪𝒔−𝑪𝒙)
𝒉
            Equation 3 
 
 
According to equation 3, the increase in drug surface area in addition to an 
increase in saturation solubility (e.g. due to nanosizing) will increase the dissolution 
rate. The dissolution process can be further enhanced by making the drug 
nanoparticles amorphous (Sigfridsson et al. 2007). 
 
Another equation that is relating to particle size and drug dissolution is the 
Prandtl equation (4) (Mosharraf and Nyström 1995). It describes the hydrodynamic 
boundary layer thickness or diffusional distance (hH) for liquid flow passing a flat 
surface: 
𝒉𝑯 = 𝒌 ( 𝑳𝟏 𝟐�
𝑽
𝟏
𝟐�
 )      Equation 4 
 
 
The diffusion distance (h) is reduced for smaller drug particles (Böhm and 
Müller 1999; Muller 2001). In turn, by decreasing the diffusion distance (h) and 
simultaneous increase in saturation solubility (Cs), the concentration gradient (Cs−Cx)/h 
will increase and the dissolution rate will consequently be enhanced.  
where: 
D  : the diffusion coefficient,  
A   : the surface area. 
Cs :  the saturation solubility.  
Cx :  the bulk concentration.  
h  : the diffusion distance   
over which the concentration 
gradient occurs. 
where: 
hH :  the hydrodynamic boundary layer. 
K  : denotes a constant. 
L   : the length of the surface in the  
      direction of flow. 
V  :  the relative velocity of the flowing 
 liquid  against a flat surface . 
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Zhao et al. (2007) reported that the dissolution rate of danazole nanoparticles 
(364 nm) within 5 min was enhanced from 35% to 100% compared to the raw (55 µm) 
danazol particles. Crystalline nano-sized celecoxib particles alone or even after 
conversion into tablets showed a dramatic increase of dissolution rate and extent 
compared to micronized drug (Dolenc et al. 2009). Hecq et al. showed that nanocrystal 
formulations of ucb-35440-3, a model poorly soluble weak base (Hecq et al. 2006 A), 
and nifidipine (Hecq et al. 2005) offered a great success regarding enhancement of 
their dissolution characteristics. 
 
1.1.4.4 Adhesive behaviour of nanosized drug particles 
 
 
Another special feature of nanonized drug particles is their higher 
adhesiveness. Nanoparticles have a tendency to adhere to surfaces (e.g. gut wall) 
because of their massive surface area and interaction forces between the particles and 
the surface (Keck and Müller 2006). Enhancement of absorption of orally administered 
nanoformulations (e.g. drug nanocrystals) can be partially attributed to particle 
adhesion to the gut wall. In this case, drug release occurs exactly at the site of its 
absorption, leading to a higher concentration gradient between gut wall and blood 
(Müller et al. 2006).   
 
The high affinity of nanoparticles to surfaces can be also exploited for local 
drug treatment.  Hassani et al. (2009) reported a size dependent deposition of 
polystyrene nanoparticles to ulcerated gastric tissue. Because of their small mass, 
smaller particles attached better to mucus layers and showed enhanced bioadhesion 
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to inflamed areas. This could be advantageous in formulating new local drug delivery 
systems to treat the chronic and resistant H. pylori infection. 
 
Budesonide loaded nanospheres also showed significant anti-inflammatory 
effects in the trinitrobenzenesulfonic acid (TNBS)-induced colitis rat model. This effect 
was explained in part due to specific adhesion and uptake of the nanospheres at the 
site of inflammation (Makhlof et al. 2009). 
 
1.1.4.5 Improved bioavailability 
 
 
Bioavailability can be defined as the rate and extent of drug absorption 
(reaching systemic circulation). Improving drug bioavailability is a major aim in 
pharmaceutical research and may help to improve patient compliance (Yang et al. 
2008).  On the basis of the above-mentioned discussions (i.e. on enhancement of drug 
surface area, saturation solubility, dissolution and adhesiveness), the bioavailability of 
poor water soluble drugs can be improved as a result of nanonization. The potential of 
using nanoparticles formation in enhancement of oral bioavailability has been shown 
to be successful for a number of different drugs. Reported examples in the literature 
include naproxen nanosuspension (with decreasing gastric irritation at the same time) 
(Liversidge and Conzentino 1995) and danazol nanosuspension (Liversidge and Cundy 
1995).  
 
Both the Cmax and AUC0–24h values of sonoprecipitated cefuroxime axetil 
amorphous nanoparticles (80 - 130 nm) were approximately two fold greater than the 
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unprocessed crystalline drug (20–50 μm), indicating a remarkable improvement in the 
oral absorption of cefuroxime axetil when administered in the form of amorphous 
nanoparticles (Dhumal et al. 2008). For BMS-488043, an HIV-attachment inhibitor, the 
Cmax increased 4.7-fold and AUC by 4.6-fold after nanosizing (Fakes et al. 2009). 
 
Another study demonstrated a clear correlation between particle size and in 
vivo exposures for UG558, an effective cardiovascular substance (Sigfridsson et al. 
2009). UG558 exhibits low solubility characteristics even with use of co-solvents or 
hydroxypropyl-β-cyclodextrin. Nanosuspensions (particle size of 190 nm, produced by 
milling), provided higher bioavailability at both investigated doses (5 and 500 μmol/kg) 
compared to microsuspensions (particle size of 12 µm). At both doses, Cmax and AUC 
for the animals receiving nanosuspensions were approximately four times larger 
compared to the dose group that received microsuspensions. These authors 
rationalized the low bioavailability of the micronized suspension to insufficient drug 
dissolution achieved within the limited small intestinal transit time. Dissolution from 
the nanometer-sized particles was faster and resulted in improved absorption over this 
narrow time window.  
 
In a recent report by Xia et al. (2010), the plasma concentration profile for 
nitrendipine nanosuspension represented a major improvement in drug absorption 
compared to the reference formulation. The Cmax and AUC0-12 values of 
nanosuspension were approximately 6.1-fold and 5.0-fold greater than that of the 
reference preparation (commercial nitrendipine tablets dispersed in 2 ml of water), 
respectively (see Figure 1-12). 
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Figure 1-12: Average plasma drug concentration versus time profiles after oral 
administration of nitrendipine nanosuspension and reference formulation. 
Source (Xia et al. 2010). 
 
Furthermore, variation in bioavailability for the fed versus the fasted state can 
be minimized using nanosized drug formulations. Figure 1-13 shows that when a 
nanocrystalline formulation of danazol (as a liquid or a capsule) effectively reduced the 
variable performance observed with the marketed product, Danocrine®. Bioavailability 
of poorly water soluble drugs in the fasted state may decrease due to the absence of 
solubility enhancing agents present in food and bile (Merisko-Liversidge et al. 2003).  
 
 
 
 
 
 
 
 
 
Figure 1-13: Effect of nanonization on fed vs. fasted danazol bioavailability 
 
Source (Merisko-Liversidge et al. 2003). 
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To summarizes, the special features of drug nanocrystals can be presented in the 
Figure 1-14.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-14: Advantages of drug nanonization. 
 Source  (Mauludin et al. 2009 B). 
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1.1.5 Commercially available nanosized drug products 
 
 
Table (1-II) lists examples of marketed products of nano-drugs. To date, all the 
marketed products containing nanonized drugs formed by top down wet milling or 
high pressure homogenization techniques. 
 
Table 1-II: Examples of marketed products containing nanonized drugs.  
 
(Nijhara and Balakrishnan 2006; Chen et al. 2010; Van Eerdenbrugh et al. 2008). 
Product, 
active 
constituent and 
developer 
Date of 
approval 
by FDA 
Therapeutic 
use 
Nanosizing 
technique 
 
Advantage of 
nanocrystals 
formulation  
TriCor® 
 
 
 
Fenofibrate, 
 Elan/Abbott 
November 
2004 
hypercholesterolemia, 
mixed lipidemia, 
hypertriglyceridemia 
Media 
milling 
Redeveloped for a 
flexible dosing 
regime and to 
prevent the need 
of administration 
with food. 
Megace ES® 
 
 
 
 
Megestrol 
acetate,  
Elan/Par 
Pharmaceuticals 
July 
2005 
Anti anorexic 
Media 
milling 
Redeveloping the 
oral suspension for 
a higher bioavaila-
bility and ease of 
administration 
(reduced dose 
volume and 
viscosity). 
Rapamune 
Sirolimus,  
Elan/Wyeth  
August 
2000 
Immunosuppressant 
Media 
milling 
Reformulation of 
the oral solution 
that requires 
refrigeration 
storage and is less 
easy to administer. 
Emend 
Aprepitant,  
Elan/Merck 
March 
2003 
Treatment of nausea 
and vomiting in 
chemotherapy 
patients 
Media 
milling 
New chemical 
entity, the 
nanocrystals 
formulation 
diminishes 
fed/fasted 
variability. 
Triglide® 
Fenofibrate, 
Skye Pharma 
May  
2005 
hypercholesterolemia, 
mixed lipidemia, 
hypertriglyceridemia 
High 
pressure 
homogeni-
zation 
Reduce fed/fasted 
variability, as for 
TriCor®. 
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1.2 Challenges of nano-drug therapy 
 
In parallel to the potential benefits of drug nanosized particles, the demerits and 
challenges have to be faced in the future. Full attention should be taken for toxicity 
that may arise with the use of nanosized drug particles (especially for long term 
treatment) (Kayser et al. 2005). It is suggested that some nanoparticles as such should 
be considered as new chemicals. The unique characteristics of nanoparticles need to 
be investigated from a toxicological point of view (De Jong and Borm 2008). Drug 
nanoparticles can become toxic due to catalytic properties and favoured cellular 
uptake (Kayser et al. 2005).  Drug nanoparticles could cause exaggerated undesired 
effects of their macro counterparts due to their larger surface area. Moreover, 
nanoparticles may cause new types of effects that are not recognised for larger sized 
particles, such as mitochondrial damage, uptake through olfactory epithelium, platelet 
aggregation, cardiovascular effects) (De Jong and Borm 2008). The issue of toxicity may 
be more serious for intravenously injected nanoparticles, as size partly affects tissue 
distribution (Moghimi et al. 2005). However, these factors should not  necessarily be 
regarded as negative, but as a warning that nanoparticles possess novel and unique 
biological characters, and accordingly the potential risks of nanoparticles may be 
different from those of the similar structured bulk material, for better or for worse 
(Rogueda and Traini 2007). 
 
Stability of drug molecules upon nanosizing should also be considered, especially 
when using high energy techniques to prepare nanoparticles. Some of organic 
molecules are highly flexible and not rigid like inorganic materials or ceramics. 
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Moreover, drug molecules may exist as polymeric, amorphous, solvated or other 
delicate forms imposing extra challenges in trying preparation of drug nanoparticles 
without affecting such structures. 
 
1.3 Microfluidics 
 
1.3.1 Introduction 
 
In recent years considerable progress occurred in the field of miniaturization 
for processing materials. Running towards smaller and smarter devices can be noticed 
clearly in different areas of our lives. As the name suggests, microfluidics is a technique 
which involves liquids and small-scale devices, at the micrometers scale (van der 
Woerd et al. 2003). Microfluidics can be defined as the science and technology that 
processes or manipulates small amounts of fluids using channels with dimensions of 
tens to hundreds of micrometers (Whitesides 2006). Microfluidics is a multidisciplinary 
research field that requires input and knowledge in fluidics, physics, microtechnology, 
electromagnetic, material science and chemistry (Tabeling 2006). Microfluidics is a 
relatively young field which emerged in the 1990s, and is expected to expand over the 
next few years due to the considerable potential applications in the pharmaceutical, 
biomedical and chemical engineering domains (Tabeling 2006).  
The following sections present information about the main features and 
applications of microfluidics. 
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1.3.2 Microfluidics and laminar flow 
 
Generally, fluid flow can be either laminar or turbulent, depending on the ratio 
between inertial to viscous forces. This relation is given by Reynolds number, Re, 
(Weibel and Whitesides 2006) (equation 5): 
 
 
       𝑹𝒆 = 𝝆𝝊𝒅
𝝁
           Equation 5  
 
Because Re is directly proportional to d, the small dimensions of microfluidic 
channels are responsible for very low Reynolds numbers. At small values of Reynolds 
number (less than 2000), the flow is governed by viscous forces and the flow pattern is 
strictly laminar (van der Woerd et al. 2003). In this case, adjacent streams of miscible 
fluids move through microchannels side by side, in parallel, without eddies or 
turbulence and mixing occurs as a result of diffusion of molecules across the interface 
between fluids. In addition to the unique behaviour displayed by fluids at low Reynolds 
number, the short length scale and volumes involved in microfluidics systems create 
other advantageous features such as high surface to volume ratios, small diffusion 
distances and high thermal transfer efficiency (DeMello 2006).  
 
where: 
ρ : density of the medium. 
υ : the velocity of flow.  
d : diameter of channel. 
μ : the viscosity of the medium. 
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1.3.3 Moving fluids in microreactors 
 
The commonly used pumping systems in microreactors are electrokinetic 
(electroosmetic and electrophoretic) and/or hydrodynamic. Generally, 
electrokinetically driven flow can be induced in channels with walls made of materials 
that are charged under experimental conditions. The enclosed fluid will be charged as 
it will contain a higher than bulk fluid concentration of counter-ions. Upon applying an 
electric potential parallel to the channel walls, this charged fluid will be attracted to 
the electrode of opposite charge, resulting in convective fluid flow (Watts and Haswell 
2003; Weigl et al. 2003). Hydrodynamic pumping exploits conventional or microscale 
pumps, notably syringe-type pumps, to manoeuvre solutions around the channel 
network (Fletcher et al. 2002). 
 
1.3.4 Fabrication of microfluidic devices 
 
Early microfluidic devices were fabricated mostly from silicon. Then, glass 
gained acceptance as a simpler and more universal substrate for microfluidics due to 
its excellent surface stability, solvent compatibility, and optical properties. However, 
polymers like polydimethylsiloxane (PDMS) and polymethylmethacrylate (PMMA) have 
been widely used recently for microfluidic fabrication due to low cost and optical 
clarity (Sommer et al. 2008). The soft lithography technique is frequently employed to 
fabricate microfluidic systems. Details of the microfabrication process by soft 
lithography have been reported (McCreedy 2000; McCreedy 2001; Fletcher et al. 
2002). 
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1.3.5 Applications of microfluidics 
 
Other synonymous terms for microfluidics are micrometer scale total analysis 
systems (µTAS) and “lab on a chip”. With µTAS, all steps of the analyses can be handled 
on a chip; these include steps of sampling, sample processing, separation and 
detection. With lab-on-chip technology, complete laboratories could be established on 
a square centimetres of chip (See Figure 1-15). 
 
 
 
 
 
 
 
 Figure 1-15: A microfluidic chip. 
Source (Schulte et al. 2002). 
The unique features of microfluidic devices have attracted users in different 
fields. In chemistry, miniaturising reactions could generate relatively pure products 
with higher yield, compared to the equivalent bulk reactions, in much shorter times 
and sufficient quantities (Fletcher et al. 2002). Microfluidics technologies could enable 
on-chip diagnosis and real-time monitoring of infectious diseases from a small volume 
of body fluids. These technologies allow integration of various assays into a single 
device (Lee et al. 2010). 
Microfluidics has also been applied in the pharmaceutical field. In research and 
development, pharmaceutical companies have directed increasing amounts of their 
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budget to improve their lead discovery and optimization processes with conventional 
methods without much success. Microfluidics promises to be a superior technology 
both for the production of new chemical entities and for screening them against a 
range of biological targets (http://www.micronit.com).  
 
1.3.6 Crystallization 
 
Crystallization is a phase change in which a crystalline product is obtained from 
a supersaturated solution (Biscans 2004). The process of crystallization involves three 
steps, supersaturation, nucleation and crystal growth, driven by supersaturation. 
 
1.3.7 Supersaturation 
 
Supersaturation is the driving force of the crystallization process. A 
supersaturated solution contains more of the dissolved substance than could be 
dissolved by the solvent under normal conditions. In general, supersaturation is 
induced in the pharmaceutical industry by temperature change, evaporation of 
solvent, chemical reaction, changing the solvent composition or a combination of 
these processes (Chen and Singh 2001; Schwartz and Myerson 2001). A supersaturated 
solution can be reached by considering the solubility-supersolubility curve for a 
substance (see Figure 1-16). The diagram can be divided into three zones, (Mullin 
2001): 
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1. The stable (unsaturated) zone; no crystallization occurs. 
2. The metastable (supersaturated) zone; no spontaneous crystallization occurs, 
unless seeded by crystals. 
3. The unstable or labile (supersaturated) zone; crystallization can occur 
spontaneously. 
 
Temperature 
Figure 1-16: Solubility/supersolubility diagram. 
 
Source  (Mullin 2001). 
 
As seen from Figure 1-16, a supersaturated solution can be generated by 
cooling or evaporation of solvent (Mullin 2001). A supersaturated solution is not in an 
equilibrium state. Crystallization will occur in such a solution in order to reduce the 
supersaturation and attain equilibrium. 
 
 
 
Co
nc
en
tr
at
io
n 
Supersolubility curve 
Solubility curve 
Labile 
Metastable 
Stable 
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1.3.8 Nucleation 
 
Nucleation (or birth of crystals) is the formation of molecular agglomerates 
within the supersaturated solution. These agglomerates can be continually formed or 
broken until it is energetically more favourable for them to bond together than to 
remain in solution (Mullin 2001). Two types of nucleation are reported (Figure 1-17). 
The term primary nucleation is applied when nucleation occurs without the aid of pre-
formed crystalline substance, whilst secondary nucleation refers to the generation of 
nuclei in the vicinity of crystals found in a supersaturated system. Primary nucleation 
can be classified into homogeneous or heterogeneous nucleation. Homogeneous 
nucleation occurs spontaneously in a clear solution, while heterogeneous nucleation 
occurs as a result of contamination of the system by a foreign matters, solids or 
scratches in glassware (Jones 2002). The energy required for heterogeneous nucleation 
is lowered in the presence of impurities allowing nucleation to occur at a lower 
supersaturation than in homogeneous systems (Myerson and Ginde 2001).  
 
 
 
 
 
Figure 1-17: Simple scheme of nucleation.  
 
Source (Adapted from (Mullin 2001)). 
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1.3.9 Crystal growth 
 
The next stage in the crystallization process is crystal growth resulting from the 
addition of solute molecules to the formed nuclei (Mohan et al. 2000).  Two major 
steps are involved in crystal growth from solution. First, mass transport of solute 
molecules or ions from solution takes place to the surfaces of crystals by diffusion, 
convection or both of them. Secondly, incorporation of materials into the crystal lattice 
through surface integration process (Jones 2002).  
Whilst supersaturation exists the two processes, nucleation and growth, 
continue to occur simultaneously. However according to the conditions, either 
nucleation or growth may predominant over the other, and hence crystals with 
different sizes and shapes can be obtained (Paul et al. 2005). The crystallization 
process is completed when the supersaturation is exhausted. In this case, the solid-
liquid system reaches equilibrium. If the equilibrium is modified by changing operating 
conditions, supersaturation can be induced again in the solution. 
 
1.3.10 Microfluidics and crystallization 
 
Miniaturizing and automating crystallization processes may be required to 
explore various methods and conditions of crystallization in a minimum time and using 
a minimum amount of material (Lounaci et al. 2006). The low sample consumption and 
the potential of processing a large number of experiments in a few cubic centimetres 
of processing equipment make microfluidics an attractive technique for both initial 
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screening and subsequent optimization of crystallization process, especially for 
macromolecules (Lounaci et al. 2007). In addition, microfluidics systems are able to 
maintain a sealed environment over several weeks to months, and provide ready 
access to observe and harvest crystals as they are grown (van der Woerd et al. 2003). 
As mentioned before (section 1.3.2), the reduction of reactor dimension results 
in small Reynolds numbers. Consequently, the flow in the microreactor is laminar and 
mixing in microreactors is mainly driven by molecular diffusion (Génot et al. 2010, Aoki 
et al. 2004). Moreover, results of dye tracer studies from previous work performed in 
our laboratory showed that the fluids introduced via the inlets of the microreactors 
remain as two separate streams along the length of a Y shape microreactor, forming a 
distinct diffusion layer in the centre of the channel (Brook 2006) (see Figure 1-18). 
 
 
 
  
 
 
Figure 1-18: Microreactor with water and dye flowing through (1mm, 25°). 
 
Source (Brook 2006). 
 
For antisolvent crystallization processes performed within microreactors, it 
was reported that the mixing time is reduced relative to the induction time of 
crystallisation, an essential requirement to form nanoparticles with uniform size 
distributions (Zhao et al. 2007). 
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In microfluidic antisolvent crystallization processes, supersaturation is 
initiated by a diffusion process and driven by mixing between the drug solution and 
antisolvent streams across the interface (diffusion layer) to drive nucleation and 
crystal growth. The degree of supersaturation can be calculated from equation 6: 
 
                                                                 
                                                           Equation 6 
 
 
 
According to Fick’s law of diffusion, drug molecules flow down their 
concentration gradient from environment of higher concentration to that of low 
concentration. Thus, the drug molecules diffuse from their solution stream towards 
the diffusion layer to compensate solute depletion as a result of nucleation and 
crystal growth (Figure 1-19).  
 
 
 
 
 
 
Figure 1-19: Diagram of diffusion layer and liquid streams. 
 
 
The description of crystallisation in such a flow regime, together with the 
presence of interacting processing variables (such as drug concentration and 
diameter of microreactors) is not easily accessible through statistical methods or 
computational fluid dynamics (Brook 2006), alternatively, an artificial neural network 
*C
CS =
where: 
S:   supersaturation ratio 
C:   solute concentration 
C*: equilibrium solubility 
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approach is employed to describe the process from key inputs and outputs (see 
Chapter 3). 
 
1.4 Aims and objectives of the thesis 
 
 When considering the preparation of nanoparticles, process control is required 
in order to generate nanoparticles with specified features and properties (Song et al. 
2008). Generation of drug nanocrystals by top-down techniques (e.g. media milling) is 
frequently used in pharmaceutical industry (Van Eerdenbrugh et al. 2009). However, 
these methods require a significant energy input, which can induce disorders, damages 
or even amorphous regions to the crystal lattice of the processed material (Price and 
Young 2005; Planins̄ek et al. 2010).  Other disadvantages include the long time of 
processing, inadequate control of size distribution and the need of relatively large 
amounts of the processed materials (De Waard et al. 2008; Kakran et al. 2010; Van 
Eerdenbrugh et al. 2009). In addition, impurities resulted from erosion of grinding 
media may contaminate the product and affect its chemical stability (Rasenack and 
Muller 2002). Moreover, it is generally found to be difficult to produce nanoparticles 
with a size below 100 nm by the top-down approaches (He et al. 2010).  
Because of the above mentioned limitations, great interest has been directed 
to alternative production processes (i.e. bottom-up approach) to prepare drug 
nanoparticles (Hu et al. 2008). However, some of the bottom-up techniques as  spray 
freezing into liquid (SFL) and supercritical antisolvent precipitation (SAS) need complex 
operating conditions and equipment requiring high pressure and/or extreme low 
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temperature (Zhao et al. 2007). Accordingly, a strong ambition of producing 
monodispersed pharmaceutical nanoparticles using less complicated nanosizing 
techniques remains. 
Particle engineering using microfluidic technique can be utilized as a cost-
effective and environmental friendly technology for the rational design and synthesis 
of nanomaterials (Chan et al. 2005; Wagner and Köhler 2005; Song et al. 2008). When 
the work in this study began in 2006, there were few reports about synthesis of 
nanoparticles within microfluidic reactors in the open literature. Such reported studies 
largely focused on the synthesis of inorganic nanoparticles, with examples including 
CdSe (Chan et al. 2003), CdS (Edel et al. 2002), TiO2 (Wang et al. 2002), Co (Song et al. 
2006) and Ag (Lin et al. 2004). Efforts to harness the advantages of microfluidics to 
generate pharmaceutically active nanoparticles, to date, are relatively few (Karnik et 
al. 2008).  
The research goal of this thesis was to test the hypothesis that microfluidic 
approach can be used to produce nanosized particles of drug substances suitable for 
enhancing the performance of drug molecules. 
The research presented in this thesis aimed to evaluate the potential of 
microfluidic nanoprecipitation as an efficient, straight forward and low-energy bottom-
up technology in the field of drug nanosizing.  Objectives included research into the 
impact of different processing conditions on particle characteristics using artificial 
intelligent software, to explore the possibility to tune the size of generated drug 
particles. The research also aimed to explore the potential of the microfluidic 
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nanoprecipitation process in preparing nanoparticles of selected drugs and formulating 
them into drug delivery formulations and furthermore, to identify the influence of drug 
nanosizing on the performance of these formulations. In order to meet this specific 
objective, three commonly used, poor water soluble corticosteroids candidates 
(hydrocortisone, prednisolone and budesonide) were investigated.  
Hydrocortisone (Figure 1-20), 11β, 17α, 21-trihydroxypregn-4-ene-3, 20-dione 
is an important and extensively used corticosteroid. It is effective as an antiphlogistic, 
immunosuppressive and antiproliferative substance with instant effect (Chen et al. 
2004). Hydrocortisone occurs as a white or almost white, crystalline powder and is 
classified as a water-insoluble drug with low bioavailability (Filipovic-Grcic et al. 2000). 
Owing to the limited aqueous solubility of hydrocortisone, co-solvents, surfactants, 
and/or complexing agents are added to obtain aqueous solutions of sufficient 
hydrocortisone concentrations. Otherwise, hydrocortisone can be formulated as a 
suspension or emulsion (Chen 1998).  
 
 
 
 
 
 
Figure 1-20: Chemical structure of hydrocortisone. 
 
 Source (Lemus Gallego and Pérez Arroyo 2002). 
 
Prednisolone (Figure 1-21), 11-β,17,21-trihydroxypregna-1,4-diene-3,20-dione, 
is a synthetic adrenal corticosteroid possessing a potent anti-inflammatory effect and 
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is commonly  used to treat  a variety of inflammatory conditions such as arthritis, 
colitis, asthma, bronchitis, certain skin rashes, and allergic or inflammatory conditions 
of the nose and eyes (Mazurek and Szostak 2006; Li et al. 2007; Goyal and Bishnoi 
2009). Prednisolone occurs as a white or almost white, hygroscopic, crystalline powder 
and exhibits a low solubility and dissolution rate in the gastrointestinal tract, which 
limits its effective absorption and bioavailability (Zhang et al. 2006). 
 
 
 
 
 
 
Figure 1-21: Chemical structure of prednisolone. 
 
Source (Goyal and Bishnoi 2009).  
 
 
Budesonide (Figure 1-22), α- and β-propyl forms of 16α,17α-butylidenedioxy-
11β,21-dihydroxypregna-1,4-diene-3,20-dione, is a potent corticosteroid with high 
glucocorticoid receptor affinity (Brogden and McTavish 1992). Budesonide occurs as a 
white to off-white, odourless, crystalline practically water insoluble powder. Like other 
inhaled glucocorticoids (IGCs), budesonide is commonly used in treatment of 
persistent asthma symptoms in children and adults due to its anti-inflammatory effect 
(Crowley 2003). Budesonide is currently marketed as nasal spray, dry powder inhaler 
and suspension for nebulization for the treatment of chronic inflammatory respiratory 
disorders (Martin et al. 2002). Its high ratio of local anti-inflammatory action allows 
minimization of the systemic side effects of the therapeutic doses (Barnes et al. 1998).  
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Figure 1-22: Chemical formula of budesonide.  
 
 Source (Gupta and Bhargava 2006). 
 
 
1.5 Thesis structure  
 
This thesis is presented in seven Chapters, in addition to the appendix. Chapter 1 
reviewed the techniques of drug nanonization and benefits of drug nanoparticles with 
a brief introduction about microfluidics and crystallization. It also detailed the aims 
and objectives of the research. Chapter 2 details the solvent-antisolvent solubility 
profiles of the drugs used in the study. In Chapter 3, the relationships between the 
different (material and processing) factors affecting microfluidic nanoprecipitation 
process using artificial neural networks are presented. Chapter 4 reports on a trial to 
exploit the microfluidic nanoprecipitation process to prepare pharmaceutical 
nanosuspensions. Chapter 5 details a comparison between the microfluidic 
nanoprecipitation, as a bottom up, and wet milling as a top down technique of drug 
nanonization. Chapter 6 details on studies the application of microfluidic 
nanoprecipitation to tailor drug nanosuspensions suitable for pulmonary delivery, and 
Chapter 7 provides general conclusions from the research work and suggestions for 
future work. 
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2 Solubility Studies 
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2.1 Introduction 
 
2.1.1 Drug solubility 
 
The thermodynamic (true or equilibrium) solubility can be defined as the 
maximum amount of a substance that dissolves in a given volume of solvent at a 
specified temperature (Bhattachar et al. 2006; Alsenz and Kansy 2007). The terms of 
kinetic and intrinsic solubility are also used in pharmaceutical reports to express drug 
solubility. Kinetic solubility is the concentration of a compound at the time when an 
induced precipitate first appears in the solution while intrinsic solubility means 
equilibrium solubility of non-ionized compounds or the neutral form of ionizable 
substances (i.e. at pH when it is fully un-ionized) (Alsenz and Kansy 2007; Baka et al. 
2008).  
Based on their solubility, drugs can be classified from “very soluble” to 
“practically insoluble” according to the British Pharmacopeia (Table 2-I) (BP 2008).  
In drug development, the aqueous solubility is an important molecular property 
for the drug to be successfully formulated because it is an essential determinant, 
together with permeability, governing drug access to biological membranes (Faller and 
Ertl 2007). If the solubility and rate of dissolution are too low, orally delivered drug 
may be excreted without the possibility of passage from the gastrointestinal tract into 
blood stream (Jorgensen and Duffy 2002). Accordingly, solubility of new molecules 
needs to be assessed at early stage of drug discovery and drug candidate selection 
process (Stegemann et al. 2007).  
                                                                                                         Drug Nanosizing Using Microfluidic Reactors       
  
47 
 
 
Drug solubility can be affected by several factors, including solvent 
composition, temperature, pH, drug solid state (amorphous, crystalline), polymorph 
type, counter ions (salt formation) and  ionic strength (Stegemann et al. 2007).  
Table 2-I: Descriptive terms of solubility according to the British Pharmacopeia 2008. 
 
 
 
 
 
One of the common approaches to measure solubility of drugs is the saturation 
shake-flask method (Peña et al. 2006). In this method excess amounts of solid drug are 
introduced into vials containing specified volumes of the selected solvents (e.g. buffer 
solutions). Then, the vials are sealed, incubated into a constant temperature bath 
(37°C or 25°C), and shaken until equilibrium is attained. After microfiltration or 
Description terms Approximate volume of solvent in milliliters  
per gram of solute 
Very soluble Less than 1   
Freely soluble From 1 To 10 
Soluble From 10 To 30 
Sparingly soluble From 30 To 100 
Slightly soluble From 100 To 1000 
Very slightly 
soluble From 1000 To 10 000 
Practically 
insoluble More than   10 000 
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centrifugation of the incubated suspensions, concentrations of the dissolved substance 
can be quantified using a suitable technique of analysis (Avdeef 2007). 
 
2.1.2 Aim of work in Chapter 2 
 
As a preliminary step for the antisolvent precipitation process, the 
experimental solubilities of budesonide, hydrocortisone, and prednisolone in ethanol 
(the solvent), water (the antisolvent) and different ethanol + water mixtures at room 
temperature (25 °C) were studied. Results of solubility were compared to the trained 
version of Jouyban−Acree model for drug solubility in ethanol-water systems (Jouyban 
and Acree 2006) to explore the predictability of this model for the tested drugs (see 
section 2.3.4). 
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2.2 Experimental 
 
2.2.1 Materials 
 
• Budesonide (99%) was purchased from Industriale Chimica s.r.l (Saronno, Italy). 
• Prednisolone (99%) was purchased from Sigma-Aldrich (MO, USA). 
• Hydrocortisone (98%) was purchased from Sigma- Aldrich (MO, USA). 
• Absolute ethanol from Fisher Scientific Ltd. (Loughborough, UK). 
• Distilled water was obtained from PurelabTM, ELGA (Buckinghamshire, UK). 
 
 
2.2.2 Solubility measurement 
 
2.2.2.1 Standard calibration curve 
 
Stock solutions of hydrocortisone, prednisolone and budesonide (1.0 mg/ml) 
were prepared by dissolving appropriate amount of substance in ethanol. Standard UV 
(V-530 UV-Vis spectrophotometer, Jasco, Japan) calibration curves were generated at 
wavelengths; 240, 247 and 247 nm for budesonide, hydrocortisone and prednisolone, 
respectively. Linearity was evaluated by linear regression analysis.  
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2.2.3 Apparatus and procedures 
 
The solubility of the tested corticosteroids in ethanol  and water mixtures was 
determined by equilibrating excess amounts of the solids at 25 °C using a shaker (Grant 
Instruments, Cambridge Ltd, England) placed in an incubator equipped with a 
temperature−controlling system maintained constant to within ± 0.2 C. After sufficient 
length of time (> 24 h), the saturated solutions of the drugs were filtered using 
hydrophilic Durapore filters (0.45 μm, Milipore, Ireland), diluted with ethanol, and 
assayed spectrophotometrically (V-530 UV-Vis spectrophotometer, Jasco, Japan) at 
wavelengths; 240, 247 and 247 nm for budesonide, hydrocortisone and prednisolone, 
respectively. Each experimental data point represents the average of three repeat 
experiments.  
 
 
2.2.4 Solubility modelling  
 
 
The prediction of the solubility profile shape is of interest and useful in the 
pharmaceutical industry to estimate the optimal co-solvent ratio or to expect the 
solubility pattern in solvent mixtures (Peña et al. 2006). Of the numerous models 
developed in recent years, the Jouyban−Acree model was found to provide acceptable 
prediction for how the solute solubility varies with both temperature and solvent 
composition. This model requires the values of experimental solubility of the drug in 
mono-solvent systems. The trained form of the Jouyban−Acree model for prediction of 
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drug solubility in ethanol and water mixtures at specific temperature (Jouyban and 
Acree 2006) is given in equation 7: 
 
( ) ( )21 2 1 2 1 2 1 21 2
, 1 1, 2 2,
458.17 194.21724.21log log logSat Sat Satm T T TC C C T T T
ϕ ϕ ϕ ϕ ϕ ϕ ϕ ϕϕ ϕϕ ϕ
− −
= + + + +  
                                                                                                                                                     Equation 7 
 
where  is the solute solubility in the binary solvent mixtures at temperature 
T (K), 1ϕ , and 2ϕ  are the volume fractions of the solvents 1 (ethanol) and 2 (water) in 
the absence of the solute, and  denote the solubility of the solute in the neat 
solvents 1 and 2, respectively. The accuracy of the the Jouyban−Acree model was 
evaluated using collected experimental solubility data from the literature and showed 
better predictions compared to a previously established log-linear model (Jouyban and 
Acree 2006).  
 
The trained Jouyban−Acree model was fitted to the experimental solubility data 
of each drug and the back-calculated solubilities were used to calculate the accuracy of 
the fit. The mean relative deviation (MRD) was calculated to check the accuracy of the 
predictions (equation 8): 
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where N is the number of data points in each set. 
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2.3 Results and discussion 
2.3.1 Calibration curves 
 
 
Details of standard calibration curves of the hydrocortisone, prednisolone and 
budesonide in ethanol are shown in Table 2-II. The calibration curves demonstrated 
excellent linearity between drug absorbance and drug concentrations over the 
measured ranges. The linear correlation coefficient (r2) for the calibration curves was 
0.998, 0.999 and 0.999 for budesonide, hydrocortisone and prednisolone, respectively. 
 
Table 2-II: Details of the U.V. calibration curves of the tested drugs. 
 
 
 
Drug λ 
nm 
1−⋅molLε
 
1−⋅ Lmolc
 
correlation 
coefficient 
calibration curve 
(A: absorbance) 
Budesonide 240 
 
14724 
to 15542 
 
2.32 × 10-6 
to 4.65 ×10-5 
0.998 
75 102106 −− ×+×= Ac
 
Hydrocortisone 247 
 
15227 
to 15517 
 
1.38 ×10-5 
to 5.51 ×10-5 
0.999 
75 104107 −− ×+×= Ac
 
Prednisolone 247 
14417 
to 16580 
6.93 × 10-6 
to 5.54 ×10-5 
0.999 
65 10210 6 −− ×+×= Ac
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2.3.2 Solubility studies 
 
Being water-miscible, pharmaceutically acceptable, of low hazard and 
commonly used as a co-solvent in pharmaceutical formulations, ethanol was chosen as 
a suitable solvent for the tested drugs.  
The experimental ethanol/water solubility profile of hydrocortisone at 25 °C is 
shown in Figure 2-1. Solubility of hydrocortisone in water was found to be 0.311 ± 0.02 
mg/ml. In the literature, the reported values of aqueous hydrocortisone solubility are 
0.4 mg/ml (Loftsson et al. 2003) and 0.391 mg/ml (Cavalli et al. 1999), and 0.28 mg/ml 
(Levine 1980). Solubility of hydrocortisone increased with the addition of ethanol up to 
a maximum of 28.4 ± 0.6 mg/ml at 80% v/v ethanol/water and then decreased to a 
value 14.7 ± 0.3 mg/ml in absolute ethanol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1: Solubility of hydrocortisone in different ethanol-water combinations at 25 
°C. 
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The experimental ethanol/water solubility profile of prednisolone at 25 °C is 
shown in Figure 2-2. Solubility of prednisolone in water was found to be 0.27 ± 0.025 
mg/ml. Larsen et al. (2005) reported a value of 0.391 mg/ml for the aqueous solubility 
of prednisolone. At the other end of the curve, solubility of prednisolone was found to 
be 24 ± 1.15 mg/ml in ethanol. In between, the prednisolone solubility was found to 
increase with increasing ethanol content a maximum value of 41 ± 1.36 mg/ml at 80 % 
v/v ethanol/water.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2: Solubility of prednisolone in different ethanol-water combinations at 25 
°C. 
 
Figure 2-3 represents the result of solubility studies of budesonide in ethanol, 
water and different ethanol-water combinations (v/v). Solubility of budesonide in 
water was measured to be 0.028 ± 0 .002 mg/ml, higher than reported in literature 
0.024 mg/ml (Bandi et al. 2004) and 0.022 mg/ml (Kinnarinen et al. 2003). The 
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solubility of budesonide increases by addition of ethanol until 40 % v/v ethanol in 
water (1.42 ± 0.01 mg/ml). Above this solvent ratio, a marked increase in budesonide 
solubility was observed with further addition of ethanol until a maximum value 35 ± 
0.61 mg/ml at 90: 10, v/v, ethanol: water, respectively, followed by a decrease to 27 ± 
0.29 mg/ml in pure ethanol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3: Solubility of budesonide in different ethanol-water combinations at 25 °C. 
 
As seen from the previous results, hydrocortisone, prednisolone and 
budesonide exhibit poor water solubility. Like other nonpolar molecules, these drugs 
do not effectively break into the lattice structure of water; accordingly, their aqueous 
solubility is low (Seedher and Bhatia 2003). However, in all three cases, solubility was 
enhanced by ethanol addition. Ethanol, a less polar solvent, is likely to be effective in 
disrupting hydrogen bonding interaction between the water molecules. This in turn 
reduces the ability of the resulting solvents (aqueous-ethanol mixtures) to squeeze out 
non-polar drug solutes (Liu et al. 2004).  
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The solubility of drugs in aqueous mixed solvents may exhibit a maximum 
indicating the higher solubility of a solid solute in a mixed solvent than in either of the 
pure solvents (Ruckenstein and Shulgin 2003). In Figures 2-1, 2-2 and 2-3, the solubility 
curves pass through maxima before returning to lower values in pure ethanol. The 
presence of these maxima is likely to be due to a complex thermodynamic basis, and 
occur as a consequence of the influence of both enthalpy and entropy effects, and no 
definitive explanation has been achieved (Granberg and Rasmuson 2000). A similar 
unusual solubility pattern has been observed for other drugs including lamotrigine, 
diazepam, clonazepam (Shayanfar et al. 2009), rofecoxib (Desai et al. 2003) and 
valdecoxib (Liu et al. 2004) in ethanol and water mixtures. 
The Jouyban−Acree model showed a good fit to the experimental solubility 
data of drugs at all composition ranges of ethanol (Table 2-III). This finding is 
confirmed by small MRD values for the back-calculated and experimental solubility 
data (Table 2-IV). The prediction procedure using Jouyban−Acree model is 
straightforward and could be preferred in solubility predictions in ethanol and water 
mixtures at various temperatures. However, it is only applicable for ethanol and water 
mixtures. Such mathematical models are helpful to optimize the solvent composition 
(solvent – cosolvent ratio) for dissolving a desired amount of a drug in a given volume 
of the solution, instead of using trial and error approach that is time consuming and 
may be costly (Shayanfar et al. 2009).  
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Table 2-III: Experimental and predicted solubilities (mg/ml) of hydrocortisone, 
prednisolone and budesonide in ethanol + water mixtures at 25 °C according to 
trained Jouyban-Acree model. 
 
 
Drug hydrocortisone Prednisolone Budesonide 
Ethanol 
in 
water 
(v/v) 
Observed 
solubility 
(mg/ml) 
Computed 
solubility 
(mg/ml) 
Observed 
solubility 
(mg/ml) 
Computed 
solubility 
(mg/ml) 
Observed 
solubility 
(mg/ml) 
Computed 
solubility 
(mg/ml) 
0 
0.31 0.31 0.27 0.27 0.028 0.028 
0.1 
0.71 0.64 0.62 0.59 0.08 0.077 
0.2 
1.12 1.28 1.30 1.26 0.20 0.21 
0.3 
2.32 2.50 3.14 2.63 0.60 0.57 
0.4 
5.40 4.77 5.23 5.33 1.42 1.43 
0.5 
8.17 8.67 9.60 10.31 4.70 3.52 
0.6 
14.70 14.48 21.80 18.36 8.50 7.95 
0.7 
22.75 21.20 32.30 28.63 17.85 15.74 
0.8 
28.40 25.49 41.00 36.66 31.00 25.60 
0.9 
23.31 23.27 38.00 35.66 35.00 31.60 
1 
14.70 14.70 24.00 24.00 27.00 27.00 
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Table 2-IV: Numerical values of the mean deviation (MD) for the predicted 
solubilities of hydrocortisone, prednisolone and budesonide in ethanol + water 
mixtures.  
 
Drug MD % 
Hydrocortisone 5.7 
Prednisolone 6.4 
Budesonide 7.2 
 
 
2.4 Conclusion 
 
The solubility behaviour of hydrocortisone, prednisolone and budesonide in 
different ethanol-water combinations at 25 °C was explored. The aqueous solubility of 
the drugs was poor and increased by addition of ethanol to maximum values, and then 
returned to a lower value in pure ethanol. The Jouyban-Acree model showed a good 
prediction for the solubility values in different ethanol-water combinations at the 
mentioned temperature. 
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3 Modelling of Microfluidic 
Nanoprecipitation Using 
Artificial Neural Networks
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3.1 Introduction 
 
3.1.1 Artificial neural networks 
 
 
Artificial neural networks (ANNs) are biologically inspired computer programs 
developed to mimic the processing ability of human brain (Agatonovic-Kustrin and 
Beresford 2000). The basic units of both, the human nervous system and of ANNs are 
the neurons. In biological model, the signals are delivered to the neurons from other 
neurons through a tree-like structure (dendrites). Then, the neuron sends out spikes of 
electrical activity through a long channel (axon), which splits into thousands of 
branches. At the end of each branch, a structure called a synapse. These structures   
convert the activity from the axon into electrical effects that can cause excitation or 
inhibition of the subsequently connected neurones (Rowe and Roberts 1998, A; 
Stergiou and Siganos 2010) (Figure 3-1).  
 
 
Figure 3-1: Diagram of biological neuron 
 
Source (Agatonovic-Kustrin and Beresford 2000). 
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Artificial neuron networks attempt to simulate this neurological processing ability 
of the human brain.  ANNs are composed of a large number of interconnected artificial 
neurons. Here, the neurons are simple mathematical processing units that receive one 
or more inputs and yield an output (Podlogar et al. 2008; Ibrić et al. 2009)(Figure 3-2). 
It is rare for artificial neural networks to have more than a few hundred or a few 
thousand neurons, whereas the average human brain contains about 100 billion 
neurons (Agatonovic-Kustrin and Beresford 2000). For each artificial neuron, every 
input has an associated weight which determines its relative importance, and the 
neuron then computes the weighted sum of all the inputs and calculates its output 
(Rowe and Roberts 1998, B; Ibrić et al. 2009). Accordingly, an artificial neuron consists 
of three basic elements (Ismail 2001) (Figure 3-2): 
1- A set of synapses (connecting links), each with its own weight or strengths. 
2- An adder, ∑, computes the weighted sum of signals. 
3- An activation function, which maps the net input signal of the neuron to an 
output signal. 
 
 
 
 
 
 
 
 
 
 
Figure 3-2: Diagram of an artificial neuron. 
 
Source (Agatonovic-Kustrin and Beresford 2000). 
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3.1.2 Network architecture 
 
 
The pattern by which the neurons are organized in ANNs is termed the 
“network architecture”. Multi-layer Perceptron (MLP), a feed-forward network trained 
by backpropagation, is considered as one of the most popular and successful network 
architectures (Rizkalla and Hildgen 2005). MLP is built of identical neurons arranged in 
layers (Figure 3-3); 
 
Input layer: which does not have computing activity and is simply used to input 
independent variables such as various significant formulation and process factors 
(inputs). 
Hidden layer (s): stay in between the input and output layers, and provide the 
interconnection between the input and output layers. 
Output layer is the last layer and is used to process outcome of the desired 
number of  dependent variables (outputs) as in vitro drug release profiles  (Sun et al. 
2003).     
 
Each layer consists of several units corresponding to neurons or nodes and 
weight connections. Neurons in each layer are fully interconnected to those in the 
subsequent layer, with links corresponding to synapses, in a way that the outputs in 
one layer will be the inputs in the next layer (Rowe and Roberts 1998, B; Takayama et 
al. 1999).  
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The number of input and output variables in the investigated operation 
determines the number of neurons or nodes in the input and output layers (Plumb et 
al. 2005). However, the number of neurons or nodes in a hidden layer depends on the 
complexity of the system being modelled (Cheng et al. 2007). Although there are some 
rules of thumb that can be used as guidance, the trial and error approach is still the 
commonly used method for selecting the number of hidden nodes (Sun et al. 2003). 
When the hidden layer possesses too few neurons, this will lead in under fitting due to 
failure in adequate detection of the signals in a complex data set. On the other hand, 
too many hidden neurons may result in some problems like over-fitting and prolonging 
the training time (Mehta 2005). Theoretically, any number of hidden layers may be 
added, but, it is generally accepted that only one hidden layer is needed for the 
majority of pharmaceutical applications (Rowe and Roberts 1998, B). 
 
 
 
Figure 3-3: Diagram of a multilayer perceptron with one hidden layer. 
 
Source (Rowe and Roberts 1998, B). 
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3.1.3 Training neural networks 
 
 
Neural networks learn through experience that is acquired through a training 
process. This feature distinguishes ANNs from conventional computer programs which 
are explicitly programmed (Rowe and Roberts 1998, B).  The process of learning 
consists of presenting the network with example data and then the weights of the 
neurons are adjusted through iterations (i.e. number of times the complete database is 
shown to the ANN (Castellanos et al. 2002), also known as epochs) until a satisfactory 
output is obtained. The method of adjusting the weights is known as the training 
algorithm. The gradient descent backpropagation algorithm is one of the most popular 
training algorithms in the domain of neural networks (Ghaffari et al. 2006). In 
backpropagation algorithms, the error in prediction is fed backwards through the 
network to adjust the weights and minimize the error, thus preventing the same error 
from happening again (Agatonovic-Kustrin and Beresford 2000) (Figure 3-4). To 
simplify, when a pattern is presented to a neural network, it makes a random 'guess' to 
predict what it might be. It then sees how far its prediction was from the actual one 
and accordingly makes an appropriate adjustment to its connection weights (Yildirim 
et al. 2008).  Generally, there are two forms of training techniques in ANNs (Rowe and 
Roberts 1998, B):  
 
Supervised training: where the network is provided with a series of matching 
input and output examples, and it learns the relationships connecting the inputs to the 
outputs.  
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Unsupervised training: (or self supervised learning), in which, the network is 
presented with input data alone and the network learns to recognize patterns in the 
data. Accordingly, these networks use no external influences to adjust their weights. 
Instead their performance is internally monitored.  
 
Supervised training is used mainly for the MLP architecture. Supervised training 
is useful for formulation research to explore the cause-and effect links between some 
inputs such as ingredients or processing conditions, and outputs (measured properties) 
(Ibrić et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4: Supervised network with backpropagation learning rule. 
 
Source (Rowe and Roberts 1998, A). 
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3.1.4 Overtraining in artificial neural networks 
 
 
A significant problem with training of ANNs is the tendency to over-train or 
overfit. In overtraining, the network performs very well on the training data set but 
possesses large generalisation error (i.e. loses the ability to predict accurately the 
unseen data set). Figure 3-5 illustrates a case of overtraining. In such cases, when the 
complexity of network is too high, the network often accommodates and learns the 
noise within the training data set. This could happen after a critical number of training 
cycles (epochs).      
 
 
 
Figure 3-5:  Overtraining in artificial neural networks. 
 
 
 
 
To minimise the prediction errors, a “test data” set can be presented to the 
network during training. When the test error stops decreasing, or alternatively starts 
to rise, this indicates that the ANN model is starting to overfit the data, and at this 
point, the training must be terminated (Sun et al. 2003; Plumb et al. 2005).  
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3.1.5 Artificial neural networks in pharmaceutical research 
 
 
Artificial neural networks were introduced into the field of pharmaceutical 
technology in 1991 by Hussain and co-workers (Hussain et al. 1991; Petrovic et al. 
2009). Since that time, ANNs have gained wide popularity as a promising modelling 
technique in pharmaceutical researches. The impetus of such popularity is the 
existence of data sets showing non-linear relationships which are difficult to be 
modelled using classical modelling techniques, such as response surface methodology 
(RSM) (Takayama et al. 2003; Ghaffari et al. 2006). 
 
Generated ANN models have been employed to produce a better fitting and a 
higher prediction performance, compared to that of regression analysis, in developing 
pharmaceutical solid dosage forms (Bourquin et al. 1998). ANNs were successfully 
applied to model controlled release drug delivery (Sun et al. 2003).  A MLP neural 
network was used to predict dissolution profiles from matrix-controlled release pellets 
(Peh et al. 2000). ANNs were employed for studying and optimization of diclofenac 
sodium dissolution from sustained release matrix tablets (Zupani Bozi et al. 1997) and 
in the optimization of a nimodipine zero-order release matrix tablet formulation 
(Barmpalexis et al. 2010). In preformulation studies, the utility of artificial neural 
networks (ANNs) was explored to determine the physicochemical properties of 
amorphous polymers (Ebube et al. 2000) and the impact of micromeritic properties 
(bulk, tapped and particle density, particle size and shape) on powder flow 
(Kachrimanis et al. 2003). Interestingly, in pulmonary drug delivery ANNs modelling 
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was successfully applied in evaluation of in-vitro: in-vivo correlations for dry powder 
inhalers (De Matas et al. 2008). 
 
 In the field of nanomedicine, ANNs also have been employed in determination 
of factors controlling the particle size in nanoemulsions (Amani et al. 2008) and to 
identify the dominant factors affecting their stability (Amani et al. 2010). ANNs also 
have offered a successful tool for nanoparticles preparation analysis and modelling. 
ANNs predictions were closer to experimental values than those obtained using 
polynomial regression analysis (Rizkalla and Hildgen 2005). ANN modelling has been 
also utilised to evaluate the pharmacokinetics of some drugs (e.g. aminoglycosides) 
(Yamamura 2003). 
 
3.1.6 Aim of work in Chapter 3 
 
 
The microfluidic nanoprecipitation is a multivariate complex process, where the 
generated particle size can be influenced by different interacting variables. Like other 
complex processes, it is difficult to be fully modelled by classical statistical techniques 
due to the non-linear relationships existing between components and/or processing 
conditions (Takayama et al. 2003; Amani et al. 2008).  This Chapter represents an 
attempt to model the effects of parameters involved in microfluidic nanoprecipitation 
process of prednisolone, as an example of the studied corticosteroids, using ANNs. 
Such a model could provide insight into relationships amongst the variables affecting 
particle size of the generated particles and aid prediction and optimization of 
processing conditions and outcomes. 
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3.2 Experimental 
3.2.1 Materials 
 
Prednisolone, ethanol and distilled water were obtained as described previously 
(see section 2.2.1). 
 
3.2.2 Data mining tool 
 
The modelling study employed a commercially available ANNs software 
(INForm v3.5, Intelligensys, UK). This software employs neural networks to model the 
complex and non-linear relationships between inputs and outputs and result can be 
presented as 3D-graphs.  
INForm v 3.5 employs a multilayer perceptron neural network of five different 
types of backpropagation learning algorithms; Standard Incremental, Standard Batch, 
RPROP (resilent backpropagation), Quickprop, and Angle Driven Learning. The key 
difference between these algorithms is the type of updating weights in the network. 
The weights are updated after processing each input for the Standard Incremental 
training process or after processing the entire training set for the Standard Batch 
training process. In RPROP, a fixed update size is used that is not effected by gradient, 
therefore, learning rate and momentum are not required (being calculated 
automatically). Calculation in Quickprop uses a second order function to update the 
weight based on measurement of the error gradient at two consecutive points, to 
accelerate the convergence over other methods. Angle Driven Learning applies the 
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principle that if the error becomes smaller, then the learning rate is increased, while if 
the error increases, the learning rate is decreased. Adjusting the weights influences the 
contribution of each input variable and therefore largely, affects the prediction of a 
network (Plumb et al. 2005; Shao et al. 2006). 
The transfer functions (activation function) in INForm v 3.5 can be linear, 
sigmoidal (symmetric- about origin- or a symmetric) or hyperbolic tangent tanh (S 
shaped and symmetrical about the origin) Intelligensys. Figure 3-6 represents the 
different activation functions and the used ways to calculate the output. Generally, 
non linear transfer functions are employed in complex transformations allowing the 
neural network to deal with a wide range of tasks (Rowe and Roberts 1998). 
 
 
 
 
Figure 3-6: transfer functions with their corresponding equations. 
 
 
3.2.3 Microfluidic nanoprecipitation  
 
The nanoprecipitation process was carried out by streams of ethanolic solution 
of prednisolone and water as antisolvent pumped through a set of microfluidic 
reactors (Epigem Ltd, UK). These microreactors were made from 
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polymethylmethacrylate (PMMA) and designed with different internal diameters and 
inlet angles (Figure 3-7). The drug solution and antisolvent flow rates were controlled 
using syringe pumps. The impact of different parameters affecting the production of 
drug particles including drug saturation level (8-24 mg/ml), solution flow rate (0.1-2.2 
ml/min), antisolvent flow rate (0.1 – 2.8 mg/ml), channels internal diameter (0.5 and 1 
mm) and inlet angle (10, 25 and 50°) was studied. All experiments were performed at 
room temperature (25 °C). 
 
 
 
 
 
 
Figure 3-7: Picture of a microreactor. 
 
3.2.4 Measurement of particle size 
 
The particle size of generated prednisolone particles was analyzed by photon 
correlation spectroscopy (PCS) using a Zetasizer® NanoS (Malvern Instruments Ltd, UK) 
yielding the mean particle diameter (Zave) of the dispersed particles. All samples were 
Inlet Inlet 
Outlet 
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measured as suspensions immediately after preparation at room temperature without 
further dilution. The mean of three measurements was taken. The instrument was 
calibrated using a NanosphereTM size standard 60 and 500 nm (Thermo Scientific 
Corporation, USA). More details about PCS analysis are found in Chapter 4 (section 
4.1.3.2).  
 
3.2.5 ANN modelling 
 
3.2.5.1 Data collection, network training and model generation 
 
 
Training of the ANNs software was performed using a set of experimental data 
consisting of fifty-three samples prepared under different processing conditions (see 
Tables 3.I and 3.II). The produced particle size was the single output, while, the 
following five variables were selected as inputs to the network: 
1. Drug saturation level (mg/ml),  
2. Solvent flow rate (ml/min),  
3. Antisolvent flow rate (ml/min),  
4. Inlet angle of fluid streams (°)  
5.  Internal diameters of microreactors (mm).  
The total data set was split into training and a validation subset by randomly 
selection of 48 samples and assigning them to the “training data set” (Table 3-I) to 
establish cause–effect relationships. The remaining 5 individual data points (Table 3-II) 
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were used as “test data”. In the back propagation algorithm, the test data set is an 
independent data set, which is reserved, and not actually used for training. The test 
data are presented to the ANNs model periodically to keep an independent check on 
the progress of the algorithm to assess the quality of model and prevent overfitting 
(Sun et al. 2003). 
Records of additional 17 experiments were used as unseen or “validation data” 
(Table 3-III) to assess the predictive ability of the generated model and to ensure that 
the relationship between inputs and outputs, based on the training and test sets are 
real.  
Overtraining was avoided using previously reported approaches through setting 
the maximum number of iterations to 1000 (i.e. the default value). Also, as mentioned 
before, the data of five individual records (i.e. 10% of the data set) were randomly 
taken out of the learning process as test data (Amani et al. 2008). The training process 
terminates when the correlation coefficient of the test data starts to decrease showing 
that the network is becoming overtrained. 
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Table 3-I:  Reactor and microfluidic experimental conditions and the observed 
particle size for training data. 
 
Sample 
No 
Saturation 
level 
(mg/ml) 
 
Solvent 
FR 
(ml/min) 
Antisolvent 
FR 
(ml/min) 
 
Angle 
(°) 
Internal 
diameter 
(mm) 
Particle 
Size 
(nm) 
1 10 0.8 1.5 10 0.5 185 
2 23 0.7 0.6 50 1.0 405 
3 18 0.9 0.9 10 1.0 298 
4 12 0.3 0.8 25 0.5 214 
5 20 1.7 1.7 50 0.5 212 
6 14 0.6 1.1 50 1.0 217 
7 10 0.9 2.2 10 1.0 95 
8 17 0.2 0.3 25 0.5 321 
9 15 2.0 1.9 50 0.5 292 
10 20 1.5 0.9 25 1.0 563 
11 8 0.6 1.4 10 0.5 195 
12 23 0.9 2.8 10 0.5 148 
13 17 1.8 1.8 50 0.5 191 
14 11 1.6 2.0 25 1.0 265 
15 21 1.8 1.4 25 1.0 438 
16 11 1.1 1.3 50 1.0 161 
17 21 1.1 1.4 25 1.0 251 
18 16 1.3 1.6 25 0.5 299 
19 22 1.4 1.0 50 1.0 742 
20 9 1.1 2.7 50 0.5 177 
21 9 0.5 1.2 50 0.5 235 
22 24 2.0 2.0 10 1.0 364 
23 16 1.0 2.3 10 0.5 153 
24 8 0.6 1.4 10 0.5 195 
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Table 3-I: (continued): Reactor and microfluidic experimental conditions and the 
observed particle size for training data. 
 
 
Sample 
No 
Saturation 
level 
(mg/ml) 
Solvent 
FR 
(ml/min) 
Antisolvent 
FR 
(ml/min) 
Angle 
(°) 
Internal 
diameter 
(mm) 
Particle 
Size 
(nm) 
25 13 1.3 1.5 10 1.0 279 
26 19 0.4 0.9 25 0.5 240 
27 12 0.3 0.3 50 0.5 269 
28 22 0.4 0.3 10 0.5 327 
29 13 1.5 2.0 50 1.0 242 
30 19 2.0 1.3 50 0.5 253 
31 17 1.8 1.8 10 1.0 269 
32 10 2.0 1.0 10 0.5 212 
33 11 0.7 0.8 25 1.0 252 
34 10 1.7 1.0 10 0.5 265 
35 24 0.1 0.1 10 0.5 327 
36 18 0.4 0.7 50 1.0 258 
37 17 0.2 0.3 25 0.5 321 
38 13 0.8 2.7 25 1.0 160 
39 23 0.1 0.2 10 0.5 338 
40 22 1.9 1.5 50 1 280 
41 19 1.6 1.5 25 0.5 242 
42 20 2.2 1.3 25 0.5 320 
43 20 1.9 1.2 25 1.0 246 
44 9 1.9 1.1 25 0.5 318 
45 11 2.0 1.2 25 1.0 329 
46 21 1.6 1.1 25 1.0 327 
47 21 1.8 1.4 25 1.0 438 
48 10 0.9 1.8 10 1.0 225 
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Table 3-II: Reactor and microfluidic experimental conditions and the observed 
particle size for test data. 
 
 
Sample 
no 
Saturation 
level 
(mg/ml) 
Solvent 
FR 
(ml/min) 
Antisolvent 
FR 
(ml/min) 
Angle 
(°) 
Internal 
diameter 
(mm) 
Particle 
size 
(nm) 
1 15 1.5 1.5 10 0.5 256 
2 24 0.1 0.1 10 0.5 327 
3 14 0.6 1.1 50 1 217 
4 17 0.2 0.3 25 0.5 321 
5 8 0.6 1.4 10 0.5 195 
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Table 3-III:  Reactor and microfluidic experimental conditions and the observed 
particle size for validation data. 
 
Sample 
No 
Saturation 
level 
(mg/ml) 
Solvent  
FR 
(ml/min) 
Antisolvent 
FR 
(ml/min) 
Angle 
(°) 
Internal 
diameter 
(mm) 
Particle 
 Size 
(nm) 
1 12 0.3 0.8 25 0.5 214 
2 20 1.7 1.7 50 0.5 212 
3 15 1.5 1.5 10 0.5 256 
4 16 1.0 2.3 10 0.5 153 
5 13 1.3 1.5 10 1 279 
6 19 0.4 0.9 25 0.5 240 
7 13 1.5 2.0 50 1 242 
8 19 2.0 1.3 50 0.5 253 
9 10 2.0 1.0 10 0.5 212 
10 18 0.4 0.7 50 1 258 
11 9 0.7 1.2 25 0.5 229 
12 19 1.9 1.2 25 1 199 
13 9 0.2 0.3 10 0.5 276 
14 14 0.5 0.5 25 1 326 
15 11 0.8 1.6 50 0.5 230 
16 18 1.6 1.1 50 1 379 
17 20 0.2 0.4 25 0.5 273 
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3.2.6 Training parameters  
 
Different training parameters were employed in preliminary experiments to 
obtain the optimum structure for the network. Table 3-IV lists the training parameters 
used in training the model. 
Table 3-IV:  The training parameters used with INForm v3.5. 
 
 
Network structure 
No. of hidden layers 1 
No. of nodes in hidden layer 6 
Backpropagation type  
Angle Driven 
Learning 
Backpropagation parameters 
Momentum factor 0.8 
Learning rate 0.7 
Targets 
Maximum iterations 1000 
MS error 0.0001 
Random seed 10000 
Smart stop 
Minimum iterations 20 
Test error weighting 0.1 
Iteration overshoot 200 
Auto weight On 
Smart stop enabled On 
Transfer function 
Output 
Symmetric 
Sigmoid 
Hidden layer Tanh 
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3.2.7 Predictability of trained models 
 
The predictive capability of the trained model was evaluated using the squared 
correlation coefficient (R2) computed against the validation data set (equation 9), with 
higher values of R2, closer to 1 indicating better predictability (Bourquin et al. 1997): 
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Equation 9 
 
Particle size error based on the difference between the predicted and the observed 
(measured) particle was also computed. 
 
 
 
 
 
 
where: 
 y :  the mean of the dependent    
         variable 
 yˆ :  the predicted value from the  
        model. 
                                                                                                         Drug Nanosizing Using Microfluidic Reactors       
  
80 
 
 
3.3  Results and discussion 
3.3.1 Microfluidic precipitation 
 
Nanodispersions of prednisolone were generated in microfluidic channels by 
mixing of drug in ethanolic solution and water (antisolvent) using hydrodynamic flow 
control. Adding antisolvent to drug solution lowers the solubility of the drug in the 
combined solvent mixture and thus generates supersaturation, which drives the 
crystallization process (see Figure 3-8). Measurement of particle size was performed 
immediately after preparation using PCS in order to minimize errors in assessing initial 
particle sizes. According to the conditions of nanoprecipitation process, the size of 
generated particles ranged from 150 - 526 nm. One of the prepared samples (record 
19 of training data set) showed much larger particle size (742 nm) than other samples 
(Table 3-VII), which may be attributed to the predominance of particle growth over 
nucleation at this particular condition of preparation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-8:  Schematic diagram of microreactor and nanoprecipitation process. 
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3.3.2 Data analysis using ANNs 
 
 After analyzing the data using ANNs, R2 values of 0.98 (for training data), 0.92 
(for test data) and 0.89 (for validation data) were obtained. These values demonstrate 
that the generated model has satisfactory predictive ability and is of good quality. 
Particle size data are presented in Tables 3-V, 3-VI and 3-VII and Figure 3-9.    
Table 3-V: The observed and predicted particle size for training data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
Observed 
particle 
Predicted 
Particle size 
error 
% 
No Size (nm) 
particle size 
(nm) 
(nm) Error 
1 185 193 8 4.3 
2 405 405 0 0.0 
3 298 288 -10 -3.4 
4 214 199 -15 -7.0 
5 212 193 -19 -9.0 
6 217 219 2 0.9 
7 95 172 77 81.1 
8 321 325 4 1.2 
9 292 281 -11 -3.8 
10 563 526 -37 -6.6 
11 195 196 1 0.5 
12 148 145 3 -2.0 
13 191 225 34 17.8 
14 265 231 -34 -12.8 
15 438 377 -61 -13.9 
16 161 199 38 23.6 
17 251 247 -4 -1.6 
18 299 272 -27 -9.0 
19 742 721 -21 -2.8 
20 177 171 -6 -3.4 
21 235 250 15 6.4 
22 364 386 23 6.0 
23 153 163 10 6.5 
24 195 196 1 0.5 
                                                                                                         Drug Nanosizing Using Microfluidic Reactors       
  
82 
 
 
Table 3-V (continued): The observed and predicted particle size for training data. 
 
 
Sample  
No 
Observed 
particle size 
(nm) 
Predicted particle 
size (nm) 
Particle size 
error 
(nm) 
% 
Error 
25 279 253 -26 -9.3 
26 240 235 -5 -2.1 
27 269 257 -12 -4.5 
28 327 336 9 2.8 
29 242 215 -27 -11.2 
30 253 245 -8 -3.2 
31 269 276 7 2.6 
32 212 228 16 7.5 
33 252 258 6 2.4 
34 265 234 -31 -11.7 
35 327 339 12 3.7 
36 258 259 1 0.4 
37 321 325 4 1.2 
38 160 144 -16 -10.0 
39 338 325 -13 -3.8 
40 280 290 10 3.6 
41 242 269 27 11.2 
42 320 310 -10 -3.1 
43 246 299 53 21.5 
44 318 333 15 4.7 
45 329 343 14 4.3 
46 327 420 94 28.4 
47 438 376 -62 -14.2 
48 225 187 -38 -16.9 
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Table 3-VI:  The observed and predicted particle size for test data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3-VII: The observed and predicted particle size for validation data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample No 
Observed 
particle size 
(nm) 
Predicted 
particle size 
(nm) 
Particle size 
error (nm) 
% 
Error 
1 256 215 -41 -16.0 
2 327 339 12 3.7 
3 217 219 2 0.9 
4 321 325 4 1.2 
5 195 196 1 0.5 
Sample 
No 
Observed 
particle size 
(nm) 
Predicted 
particle size 
(nm) 
Particle size 
(error) 
% 
Error 
1 214 199 -15 -7.0 
2 212 193 -19 -9.0 
3 256 215 -41 -16.0 
4 153 163 10 6.5 
5 279 253 -26 -9.3 
6 240 235 -5 -2.1 
7 242 215 -27 -11.2 
8 253 245 -8 -3.2 
9 212 228 16 7.5 
10 258 259 1 0.4 
11 229 302 73 31.9 
12 199 274 75 37.7 
13 276 195 -81 -29.3 
14 326 254 -72 -22.1 
15 230 244 14 6.1 
16 379 324 -55 -14.5 
17 273 289 16 5.9 
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Figure 3-9: The differences between the experimentally measured and predicted 
particle size for the validation data set. 
 
 
3.3.3 Effects of the variables on the particle size 
 
 
As mentioned before, the process of particle formation within microfluidic 
reactors involves three main steps; creation of supersaturated solution (due to solvent 
change), formation of drug nuclei (nucleation) and eventually growth of the formed 
drug nuclei. It is generally regarded that a higher level of supersaturation in anti-
solvent crystallization increases the nucleation rate relative to growth rate resulting in 
smaller size crystals (Su et al. 2007).  
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In a previous report (Amani et al. 2008), an approach comprising 3D-graph 
investigations to provide relationships about the input variables and output was 
introduced. This method involves plotting the 3D-graphs obtained from the optimized 
network showing changes of an output against two input variables, while keeping the 
remaining inputs fixed. In this work, 3D-graphs of antisolvent flow rate-solvent flow 
rate-particle size were generated from the optimized ANNs model representing low, 
medium and high values of saturation level (i.e. 10, 16 and 22 mg/ml), as well as 
different values for angle (10, 25 and 50 °) and diameter (0.5 and 1 mm). The 3-D plots 
are illustrated in Figures 3-10, 3-11 and 3-12. 
 
Overall, the details in Figures 3-10, 3-11 and 3-12 confirm the non linearity and 
complexity of relationships between the studied input variables in the 
nanoprecipitation process. The information gained by parameter fitting will be useful 
in understanding and predicting how the size of generated particles is affected by 
these variables. 
 
3.3.4 Effect of antisolvent flow rate 
 
 
From Figures 3-10, 3-11 and 3-12, it can be seen that the flow rate of 
antisolvent during the microfluidic nanoprecipitation process plays a major role in 
determining particle size. The particle size of the precipitated drug is decreased by 
increasing flow rate of the antisolvent (see Figure 3-10 (1.1)). This is due to the higher 
initial level of supersaturation leading to a high nucleation rate which depleted the 
solute rapidly, and thus many small nuclei were formed (Zhao et al. 2007).  
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3.3.5 Effect of solution flow rate 
 
In contrast to the antisolvent flow rate, increasing the flow rate of prednisolone 
solution may have an opposite effect on particle size.  The increased volume of drug 
solution, especially when containing medium or high concentrations of prednisolone 
(see Figure 3-10 (1.4)), increases the solute concentration on the surface of formed 
particles and consequently promote particle growth and formation of larger particles 
(Dirksen and Ring 1991; Zhao et al. 2007).   
 
Also, it can be noticed that at higher flow rate of both drug solution (at high 
drug concentration) and antisolvent and in microreactors with the larger diameter, 
there is a tendency of formation of larger drug particles (see Figure 3-10 (1.6)). This is 
thought to be caused by the incomplete mixing of the solvent with the antisolvent (not 
enough residence time) in the mixing channel at a higher flow rate so that the solvent 
diffusion and transfer  process was not completed (Zhang et al. 2008). The induced 
incomplete mixing at a higher flow rate may result in a non-uniform local 
supersaturation, thereby generating larger particles with wider size distribution. 
 
3.3.6 Effect of different inlet angles 
 
 
In most cases, it was observed that sharper inlet angles (10° and 25°) resulted 
in slightly smaller size of particles (e.g.  see Figures 3-10 (1.1), 3-11 (2.1), 3-11 (3.1)). 
This is thought to occur due to sharper inlet angles allowing the two inlet flows to 
meet and flow down the outlet without causing any disruption to either flow. In a 
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previous work, computational fluid dynamics (CFD) simulation studies showed that 
larger areas of no/low velocity (stagnant zones) appeared in higher inlet angles which 
accounted for larger particle formation (Brook 2006). However, this effect only played 
a minor influence on particle size as shown by the similar patterns in (Figures 3-10, 3-
11, 3-12).  
 
3.3.7 Effect of internal diameter of microreactors 
 
 
The effect of internal diameter of microfluidic reactors on drug particle size is 
complex and a clear pattern is not easily revealed from the 3D-graphs. However, it can 
be noticed that at low values of solvent, antisolvent flow rate and drug saturation 
level, a smaller microreactor internal diameter resulted in the formation of smaller 
particles. For example, curves [1.1 and 1.2 in Figure 3-10], [2.1 and 2.2 in Figure 3-11], 
[3.1 and 3.2 in Figure 3-12] can be compared. This finding may be attributed to 
improved mixing performance due to reduction of diffusion length across the 
microreactors (Aoki and Mae 2006). 
 
3.3.8 Effect of drug saturation level 
 
 
The degree of drug supersaturation is affected by drug concentration in the 
solution stream.  Generally, the size of precipitated drug particles is influenced by drug 
saturation level by two different ways. First, by increasing drug saturation level, the 
higher supersaturation may lead to a faster nucleation rate and formation of smaller 
particles.  In addition and opposite of this behaviour, higher supersaturation levels 
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favour particle growth by promoting condensation and/or coagulation (Matteucci et al. 
2006; Dong et al. 2009).  
 
The effect of drug saturation level on the microfluidic nanoprecipitation of 
prednisolone appears complex. It can be noted that larger particles are formed with 
high saturation levels of prednisolone and this effect is more pronounced at high 
solvent and low antisolvent flow rates (see Figure 3-10 (1.6)). At a higher 
concentration, a large number of nuclei formed in the solvent/antisolvent solution 
which led to particle aggregate and thus formed larger nanoparticles. The contribution 
of viscosity may also be considered here. The viscosity of drug solution increased with 
increasing concentration, which weakened the mutual diffusion between the drug 
solution and antisolvent and thus resulted in non-uniform supersaturation and 
formation of larger particles (through particle growth and/or agglomeration) (Zhang et 
al. 2010). This finding also agrees with a previous report for crystallisation of BaSO4 
nanoparticles in microreactors (Su et al. 2007).  
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Figure 3-10: 3D plot of particle size (nm) predicted by the ANN model (Angle 10°). 
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Figure 3-11: 3D plot of particle size (nm) predicted by the ANN model (Angle 25°). 
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Figure 3-12: 3D plot of particle size (nm) predicted by the ANN model (Angle 50°). 
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3.4 Conclusion 
 
The microfluidic nanoprecipitation is a complex process, where different 
interacting processing variables can affect the generated drug particle size.  As result, 
ANNs has been employed to study and model this process. ANNs generated a model 
representing nanoprecipitation of prednisolone in microfluidic reactors. The impacts of 
process conditions and microreactor setup on particle size of precipitated material 
were investigated after the training and validation. Average particle size decreased 
markedly with increasing antisolvent flow rate within the microreactors. Increasing 
drug concentration resulted in generation larger particles. Sharper inlet angle and 
smaller internal diameter resulted in smaller drug particle sizes. The findings of this 
study can be used to guide preparation of drug nanosized particles in the following 
Chapters. 
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4 Preparation of Hydrocortisone 
Nanosuspension by a Bottom-
up Procedure Using 
Microfluidic Reactors 
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4.1 Introduction 
 
4.1.1 Pharmaceutical nanosuspensions 
 
 
Pharmaceutical nanosuspensions are liquid dispersions of submicron solid drug 
particles (nanocrystals). Although the term “nanocrystals” implicates a crystalline 
structure, the particles can be crystalline, partially crystalline or completely 
amorphous. The dispersion medium can be water, mixtures of water with other non-
aqueous media or non-aqueous media. Surfactants and/or polymeric are used to 
stabilize these dispersions (Möschwitzer et al. 2004; Rabinow 2004). 
 
4.1.2 Manufacturing of drug nanosuspension 
 
 
The production techniques to produce drug nanosuspension can be classified 
into top down and bottom up technologies (see Chapter 1). Specifically, high pressure 
homogenization, media milling are the commonly used methods for nanosuspension 
preparation.  
 
4.1.3 Characterization of nanosuspension 
 
4.1.3.1 Particle size characterisation  
 
In nanosuspensions, characterisation of particle size is essential to have 
information about particle size of the systems, particle size distribution and changes in 
size over time.  The technique of photon correlation spectroscopy, PCS, (or dynamic 
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light scattering, DLS) can be used for rapid and accurate determination of the mean 
particle diameter of nanosuspensions. In such dispersed systems, particles undergo 
random “Brownian motion” induced by the bombardment of solvent molecules that 
themselves are moving because of their thermal energy. Smaller particles move faster 
than larger particles (http://www.malvern.com). The velocity of the Brownian motion 
can be identified by the translational diffusion coefficient (D). When a colloidal 
dispersion is illuminated by a beam of laser, the intensity of the scattered light 
fluctuates at a rate that is dependent upon the size of the particles. By analysis of the 
time dependence of the intensity fluctuation, the diffusion coefficient (D) of the 
particles can be obtained. Consequently, the mean particle size (called Z-average) can 
be calculated by applying the Stokes-Einstein equation (equation 10) (Keck 2006); 
 
 
      
   𝒅𝑯 = 𝑲 𝑻
𝟑 𝝅 𝜼 𝑫         Equation 10 
 
 
 
Dynamic light scattering measure the hydrodynamic diameter (see Figure 4-2), 
which is the diameter of a sphere that has the same translational diffusion coefficient 
as the particle being measured (http://www.malvern.com). 
 
 
 
where: 
d (H) : hydrodynamic diameter. 
D       : translational diffusion coefficient. 
k        : Boltzmann’s constant. 
T        : Absolute temperature. 
 η        : viscosity of the medium. 
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Figure 4-1: The hydrodynamic diameter obtained by photon correlation 
spectroscopy. 
 
Source (http://www.malvern.com). 
 
 
In addition, a polydispersity index (PDI) can be calculated as a measure for the 
width of the size distribution. Polydispersity is determined according to the equation 
below (equation 11) (Zili et al. 2005): 
 
Polydispersity Index =  
 𝐃 (𝟎.𝟗) – 𝐃 (𝟎.𝟏)
𝑫 (𝟎.𝟓)   Equation 11 
 
 
 
A PDI value of around 0.1–0.25 indicates a fairly narrow size distribution 
whereas a PI value of 0.5 or greater indicates a very broad distribution (Patravale et al. 
2004). 
where: 
D (0.9): particle size  
immediately above the sizes  
of the 90% of the nanoparticles. 
 
D (0.5): particle size  
immediately above the sizes  
of the 50% of the nanoparticles. 
 
 D (0.1): particle size  
immediately above the sizes  
of the 10% of the 
 nanoparticles. 
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4.1.3.2 Zeta potential 
 
In addition to particle size, an important characteristic of nanoparticles in 
suspension is their zeta potential. Suspended particles usually acquire a charge, which 
occurs due to the dissociation of surface functional groups or adsorption of charged 
species. Developing a charge at the particle surface affects the distribution of ions in 
the surrounding interfacial region, resulting in an increased concentration of ions of 
opposite charge (counter ions) to that of the particle, close to the surface. Thus an 
electrical double layer is created surrounding each particle. This double layer can be 
distinguished into two parts; an inner layer (Stern layer), in which the ions bound 
relatively tightly to the surface, and an outer (diffuse) layer where they are less firmly 
associated (http://www.malvern.com). Usually, the number of counter ions in the 
Stern layer is less than that needed to neutralize the surface charge and balance 
neutralization occurs in the next layer (Li and Tian 2002). Zeta potential (ζ ) is the term 
quantifying the  potential between the tightly bound surface liquid layer (shear plane) 
of the particle and the bulk phase of the solution. The potential in this region decays 
with increasing distance from the surface until, at sufficient distance, it reaches the 
bulk solution value conventionally taken to be zero (Figure 4-3).  
Experimentally, the surface potential and the Stern potential are not measured. 
However, the zeta potential can be determined by measuring the mobility of the 
particles in an applied electrical field (Li and Tian 2002). The zeta potential (ζ) is 
calculated from electrophoretic mobility using the Henry equation (12) (Agnihotri and 
Vavia 2009): 
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𝑼𝑬 = 𝟐𝜺𝜻𝒇(𝑲𝜶)
𝟑𝜼
   Equation 12 
 
 
The presence of the zeta potential can give an indication of the potential 
stability of the colloidal system. With negative or positive zeta potential, particles in 
nanosuspension will repel each other and the tendency for the agglomeration can be 
minimized. 
 
 
 
 
 
 
Figure 4-2: Schematic representation of zeta potential. 
 
Source (http://www.malvern.com). 
 
 
 
where: 
UE : the electrophoretic mobility. 
 ε : the dielectric constant of the  
suspending medium. 
 ζ: Zeta potential 
η : is the viscosity of the medium 
 K : is the Debye-Hückel parameter.  
 f(Ka) : a correction factor that takes into  
account the thickness of the double layer  
and particle diameter (a).  
The K unit is a reciprocal length.  
1/K is frequently described as the thickness  
of the electrical double layer.  
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4.1.3.3 Crystalline state and particle morphology 
 
 
Changes in drug crystalline state, such as polymorphic changes or conversion to 
amorphous forms, and/or changes in particle morphology may occur during 
nanosuspensions preparation. This in turn could affect the performance of these 
formulations. The solid state of the drug particles as well as the extent of the 
amorphous fraction can be studied using X-ray diffraction analysis and confirmed by 
differential scanning calorimetry. For particle morphology, the techniques such as 
scanning electron microscopy, transmission electron microscopy or atomic force 
microscope can be used (Patravale et al. 2004). 
 
4.1.3.4 In vitro and in vivo characterization 
 
As discussed in Chapter 1, the benefits of increasing drug saturation solubility 
as well as enhancing dissolution velocity can be provided by nanosuspension. 
Separation of undissolved drug particles is important for sampling during dissolution 
testing. Typically, membrane filters of small pore diameters (as 0.22 μm filter) can be 
used for this purpose. However, the risk of permeation of undissolved drug particles is 
significant for sizes below 400 nm. Alternatively, techniques of turbidimetry (i.e. the 
increase of transmittance with dissolution of nanoparticles), potentiometry and 
solution calorimetry have been applied for testing dissolution of nanoparticles (Kayaert 
et al. 2010). Assessment of in-vivo performance of nanosuspension formulation is 
important to establish the in-vitro/in-vivo correlation (Patravale et al. 2004).  
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4.1.4 Nanosuspension in drug delivery 
 
Recently, nanosuspensions have been used for drug delivery. Contrary to other 
lipidic systems, like liposomes and emulsions, nanosuspensions can be used for 
formulating compounds that are insoluble in both water and oils (Rabinow 2004). 
Another striking advantage of drug nanosuspensions is that these systems can be 
administered by various routes, including oral, pulmonary, ocular or even parenteral 
route (including intravenous). Compared to solution dosage forms for poorly soluble 
drugs, nanosuspension formulations can be prepared without resorting to relatively 
large amount of organic co-solvents, thereby reducing the in vivo interference and 
potential toxicological effects caused by the co-solvents. In contrast with solution 
formulations, the concentration of nanosuspension is not limited by solubility in the 
vehicle; thus a wider dose range can be achieved (Chiang et al. 2009). Unlike drug 
powder formulations, nanosuspensions have prewetted particles and possess superior 
content uniformity which may result in greater confidence of delivery and 
reproducibility.  
 
Oral nanosuspensions have been prepared to enhance the rate and extent of 
the absorption of poorly soluble drugs. Also, the ratio of fed/fasted ratio can be 
reduced with enhancing dose proportionality. 
 
For parenteral use, nanosuspensions of poorly water-soluble drugs can be 
formulated without the need of co-solvents. The use of co-solvents (as in parenteral 
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solutions) may induce anaphylactoid reactions, pain when injected and drug 
precipitation after dilution of the vehicle in the blood (Rabinow 2004).  
 
Ophthalmic nanosuspensions offer advantages for drugs of poor solubility in 
lachrymal fluids. Nanosuspensions are able to prolong residence time in a cul-de-sac 
and avoid high tonicity generated by water soluble drugs. Research in Chapter 5 
involves a study of ocular nanosuspension of hydrocortisone compared to solution 
dosage form. 
 
Pulmonary nanosuspensions with tailored particle sizes have been also 
developed for pulmonary delivery. Aqueous nanosuspensions can be nebulized using 
different nebulizers for lung delivery. In conventional micron sized suspensions, the 
drug particle has a comparable size to that of the aerosol with statistical 
inhomogeneity in incorporating of drug particles within the carrier droplets. 
Nanosuspensions would improve homogeneity by increasing the number of drug 
particles per droplet (Jacobs and Muller 2002; Rabinow 2004).  Chapter 6 presents 
more details about pulmonary nanosuspension.   
 
 
4.1.5 Ostwald ripening and drug nanosuspension 
 
As observed in highly dispersed systems, Ostwald ripening can occur in the case 
of drug nanosuspensions. Ostwald ripening means a reduction in size of the finest 
particles and the subsequent growth of larger particles (Van Eerdenbrugh et al. 2008).  
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The dominating factor behind the Ostwald ripening process is the variation in 
saturation solubility between particles due to difference in their sizes (Shukla et al. 
2009), as discussed in Chapter 1. As a result of their higher saturation solubilities, 
higher drug concentrations can be found in solution around the very small particles 
and, oppositely, lower drug concentrations are formed near the surface of larger drug 
particles. Under the effect of concentration gradient, drug molecules will diffuse to the 
lower concentrations near larger particles. Accordingly, supersaturation and drug 
crystallization occurs resulting in growth of the larger particles. In the same time, the 
drug concentration in the vicinity of smaller particles will be below the saturation 
concentration, and thus new amounts of drug will be dissolved. The overall result will 
be that the fine particles become smaller and bigger particles larger (see Figure 4-1). 
This continuous process may finally lead to the disappearance of the fine particles and 
the mean particle size shifts to higher values (Muller 2001).  
 
 
 
 
 
 
Figure 4-3: Diagram representing the Ostwald ripening process. 
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4.1.6 Tangential flow filtration  
 
 
Concentrating dilute drug nanosuspensions in order to be suitable for drug 
delivery represents an experimental challenge. The use of methods like 
ultracentrifugation for processing colloidal drug nanoparticles may lead to the 
formation of pellets which are difficult to redisperse due to aggregate formation 
(Dalwadi and Sunderland 2008).  Tangential flow filtration, TFF, (also known as cross 
flow filtration) is a mild and economic process that can be used to concentrate samples 
from millilitres to thousands of litres (http://www.pall.com). TFF is exploited in the 
field of biotechnology with expanding application to process nano-sized 
pharmaceutical colloids (Dalwadi et al. 2005; Dalwadi and Sunderland 2007). 
 
In the TFF technique, the feed stream passes parallel, rather than perpendicular 
as in normal filtration, to the membrane  face as one portion passes through the 
membrane (permeate) while the remainder (retentate) is recirculated back to the feed 
reservoir (see Figure 4-4). The flow of sample stream across the membrane surface in 
TFF sweeps away aggregating molecules that may form a membrane-clogging gel 
(http://www.pall.com). By selecting a filter of defined pore size, the drug nanosized 
particles can be retained while the dispersing fluid can be removed.  TFF can be scaled 
up easily and can be conducted under aseptic conditions (Van Buitenen and Verrijk 
2003).  
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Figure 4-4: Tangential Flow Filtration Process, (A): TFF prevents build up of particles 
at the surface   (B): TFF prevents rapid decline in flux rate. 
Source (http://www.pall.com). 
 
 
  
4.1.7 Aim of work in Chapter 4 
 
The aim of research reported in this Chapter was to investigate the feasibility of 
preparing pharmaceutical nanoformulations (hydrocortisone nanosuspensions) based 
on the microfluidic nanoprecipitation technique. Characterization and physical stability 
of the prepared nanosuspension were also performed. 
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4.2 Experimental 
 
4.2.1 Materials 
 
• Hydrocortisone, ethanol and water (see section 2.2.1). 
•  Hydroxypropylmethylcellulose, HPMC (3.5-5.6 cP, 2% w/v in H2O) was 
purchased from Shin-Etsu chemical Ltd (Tokyo, Japan). 
• Sodium lauryl sulphate, SLS was purchased from Sigma-Aldrich (MO, USA). 
•  Kollidon© 30 (PVP K30), was purchased from BASF Aktiengesellschaft 
(Ludwigshafen, Germany). 
 
4.2.2 Production of hydrocortisone nanosuspension 
 
Drug solution (100 mg/10ml) in ethanol and water were pumped in a 
microfluidic reactor (10° inlet angle and 0.5 ml internal diameter) at flow rate 1 to 2.5 
ml/min respectively. The choice of experimental parameters is based on outcome of 
ANNs studies and results of preliminary experiments. Directly after emerging from the 
microfluidic reactor, the resulting drug dispersion was introduced to 100 ml of 
aqueous solution of stabilizers (0.5 % w/v PVP + 0.2% HPMC w/v + 0.1 % w/v SLS) with 
continuous stirring at 2000 rpm with a propeller mixer (Figure 4-5). The resultant 
suspension was then kept at room temperature under reduced pressure (- 635 mm Hg) 
for 5 hours in order to remove ethanol from the aqueous dispersion (Pignatello et al. 
2006; Kumar et al. 2008). 
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Figure 4-5: Schematic diagram of the preparation of the nanosuspension. 
 
 
4.2.3 Determination of the drug content 
 
The HC content in nanosuspension was assayed spectrophotometrically (V-530 
UV-Vis spectrophotometer, Jasco, Japan) at 247 nm for the drug content after 
solubilization in ethanol and dilution.  
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4.2.4 Concentration of nanosuspension 
 
Hydrocortisone nanosuspension was concentrated at 20 psi transmembrane 
pressure (TMP) on a Minimate tangential flow filtration (TFF) system with an Omega 
5K membrane (PALL Scientific, USA). The mode of concentration was adopted, where 
the nanosuspension was circulated through the TFF system using a peristaltic pump 
back to a reservoir until it concentrated to a suitable volume (Figures 4-6 and 4-7).  
 
4.2.5 Particle size measurement 
 
The particle size of the produced dispersed systems was analyzed by photon 
correlation spectroscopy, PCS, (Zetasizer® NanoS, Malvern Instruments, UK) at room 
temperature yielding the mean particle diameter of the suspension. All samples were 
analyzed in suspension after particle preparation without further dilution. The 
measured parameters by PCS are the average particle size diameter (ZAve) and the 
polydispersity index (PDI). The mean particle size of three measurements was taken. 
The instrument was calibrated using a NanosphereTM size standard, 500 nm (Thermo 
Scientific Corporation, USA). 
 
4.2.6 Zeta potential measurement 
 
Zeta potential of HC NS was measured by a zeta meter (Zetasizer®, NanoS, 
Malvern Instruments, UK) at room temperature. Mean and standard deviation of three 
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determinations were taken. A zeta potential transfer standard® -68 mV ± 6.8 (batch 
number 12091, Malvern instruments Ltd, UK) was used to calibrate the instrument. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6: The Minimate® TFF system. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7: Schematic representation of tangential flow filtration (TFF) process. 
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4.2.7 Characterization of morphology of particles 
 
Samples of unprocessed HC were examined using scanning electron microscopy 
by the Quanta 400 SEM (FEI Company, Cambridge, UK) after being mounted onto a 
graphite layer on an aluminum cylinder under vacuum.   
Characterization of external morphology of HC nano-sized particles in 
suspension was determined using transmission electron microscopy (TEM) (JEM-
1200EX, Japan Electron Optics Laboratory Corporation, Japan) operated at 120 kV.  A 
drop of HC nanosuspension was applied on the surface of copper grid and dried at 
ambient temperature. Due to the poor conductivity of organic samples, negative 
staining with an aqueous 2% uranyl acetate solution was applied for 2 min before TEM 
measurements. The sample was introduced into a TEM (JEM-1200EX, Japan Electron 
Optics Laboratory Corporation, Japan) operated at 120 kV. 
 
4.2.8 Differential scanning calorimetery analysis 
 
A differential scanning calorimeter (TA Q2000, USA) was employed to obtain 
DSC thermal profiles of hydrocortisone. Samples of processed and unprocessed HC 
(≈4mg) were run at a scanning rate of 10 °C/min under nitrogen atmosphere. The 
temperature for the scan ranged from 20 to 250 °C. Processed HC solid sample was 
gathered from the nanosuspension by centrifugation using an Avanti ultracentrifuge 
(Beckmann, USA) operating at 4°C and rotate speed of 25000 rpm for 30 min. The 
upper clear water was removed and the remained residue was dried in electrical 
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heated vacuum desiccators at the temperature of 40°C and - 635 mm Hg vacuum. The 
DSC instrument was calibrated for temperature and heat flow responses using high 
purity indium.  
 
4.2.9 X-ray powder diffraction  
 
X-ray powder diffraction patterns of dried HC samples were obtained using a 
Siemens D5000 diffractometer (Siemens, Germany), using Cu Kα radiation 
(λ = 1.5418 Å). Drug samples (processed and unprocessed HC) were scanned over an 
angular range of 2–50° 2θ, with a step size of 0.05° and a count time of 3 s per step. 
Samples were rotated at 30 rpm during analyses. The generator was set to 40 kV and 
30 mA. A corundum standard was employed to calibrate the x-ray machine. 
 
4.2.10 Physical Stability Study 
 
Physical stability of the obtained HC nanosuspension was investigated at 25°C. 
The HC nanosuspension was stored in screw-capped amber-glass bottle and changes in 
appearance, particle size and polydispersity index were recorded over the period of 3 
months.  
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4.3 Results and discussion 
 
4.3.1 Preparation and stabilization of nanosuspension 
 
 
As illustrated in Figure 4-8, the precipitation process within the microreactor 
starts with supersaturation initiated by diffusion and mixing between the solvent and 
antisolvent streams across the interface (diffusion layer) to drive nucleation and crystal 
growth. Solute depletion from the diffusion layer as a result of nucleation and particle 
growth will be compensated by replenishments from drug solution stream. 
Micromixing time (τm) in “Y-shape” microreactors was found to be less than induction 
time of crystallisation (τi), which is essential to form nanoparticles with uniform size 
distributions (Zhao et al. 2007). 
 
 
 
 
 
 
 
 
 
Figure 4-8: Schematic representation of nanoprecipitation process within a 
microreactor. 
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 The HC nano-sized particles were generated using a 10°, 0.5 mm microreactor 
with drug concentration of 10 mg/ml and flow rates of 1:2.5 ml/min, solvent: 
antisolvent, respectively. Selection of these parameters was made after carrying a set 
of preliminary experiments (see the appendix) with the help of research findings in 
Chapter 3.  The particles produced (265 ± 32 nm) (Figure 4-9, A) were rapidly 
introduced to an aqueous solution of stabilizers under stirring in order to prepare HC 
NS. The mean diameter of particles was found to increase to 500 ± 64 nm upon the 
dilution process (Figure 4- 9, B). This size enlargement may be attributed to particles 
aggregation. For the prepared hydrocortisone nanosuspension (HC NS), the 
polydispersity index (PDI) was found to be 0.21 ± 0.03 indicating a good distribution 
profile. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-9:  Particle size distribution of hydrocortisone nanosuspension, before 
dilution (A) and after dilution (B).
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During nanosuspension preparation, additional surfaces and interfaces are 
generated. The positive value of Gibbs free energy change, associated with the 
formation of additional interface, indicates the nanosuspensions formed are 
thermodynamically unstable. Particle agglomeration occurs in order to minimize the 
total energy in such systems (Van Eerdenbrugh et al. 2008). Accordingly, careful 
selection of stabilizer(s) is needed in formulation of nanosuspension to stabilize the 
generated nano-sized particles and provides an adequate barrier against inter particle 
forces and agglomeration. 
 A mixture of (0.2% HPMC + 0.5% PVP+ 0.1% SDS) was added to the aqueous 
phase in order to stabilize the hydrocortisone nanosuspension. A small amount of PVP 
(2mg/ml) was also added in the organic phase.  Steric stabilization can be achieved by 
adsorbing polymers, HPMC and PVP onto the particle surface. When the particles 
approach each other, the osmotic stress created by the encroaching steric layers keeps 
the particles separated (Kesisoglou et al. 2007). Electrostatic stabilization can be 
provided by adsorbing charged molecules (SDS, anionic surfactants) onto the particle 
surface. Charge repulsion provides an electrostatic barrier to particle aggregation. 
Placement of small amount of stabilizer in the organic phase is also helpful where the 
polymers chains are more available to precipitating drug particles upon mixing 
avoiding the requirement to diffuse across the interface from the bulk aqueous phase 
to the organic phase. Such a reduction in time for diffusion of polymer to drug surface 
leads to more rapid stabilization against coagulation (Matteucci et al. 2006). In the 
absence of this considerable energy barrier, the suspension containing hydrocortisone 
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only showed particle growth immediately after preparation in order to reduce the 
system free energy.   
Figure 4-10 shows a photograph of the HC nanosuspension. The suspension 
shown is translucent, indicating that the hydrocortisone particles are in the nanosized 
colloidal range (Kamiya et al. 2009). 
 
 
 
 
 
 
 
 
 
 
Figure 4-10: Appearance of hydrocortisone nanosuspensions, 2 weeks after 
preparation. 
 
 
 
 
 
 
4.3.2 Concentration of nanosuspension 
 
Following nanosuspension formation, another crucial step for creating a 
suitable pharmaceutical product is to increase drug content. The TFF process, as 
discussed in section 4.1.5, was used to concentrate the HC NS. As seen from Table 4-1, 
drug concentration was adjusted to 1 mg/ml using TFF while mean particle size and PDI 
were not affected.   
A 
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Table 4-I: Impact of concentration by tangential flow filtration of hydrocortisone 
nanosuspension. 
 
 
 
Formulation 
Drug content 
(mg/ml) 
Mean particle size 
(nm) 
PDI 
 
Hydrocortisone 
nanosuspension 
Before After Before After Before After 
0.6 1 500 500 0.21 0.21 
 
 
 
 
 
4.3.3 Particle morphology 
 
 
Figures 4-11 and 4-12 show the SEM micrograph of unprocessed HC particles 
and TEM image of HC nanosuspensions. Unprocessed HC particles showed irregular 
shapes with particle size over 5 µm. The particles generated through nanoprecipitation 
within microreactors were primarily spherical with smooth surface with a diameter 
slightly less than 500 nm, the diameter obtained by PCS. This result was expected 
because the sizes determined from PCS includes any solvation shell present and should 
therefore be the same or possibly slightly larger than those obtained from other 
methods (Aboofazeli et al. 2000).  
 
 
                                                                                                         Drug Nanosizing Using Microfluidic Reactors       
  
116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-11: SEM micrograph of unprocessed hydrocortisone.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-12: TEM micrograph of dried HC nanosuspension (the bar scale is 0.5 µm). 
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4.3.4 DSC and X-ray analyses 
 
 
The crystalline structure of HC before and after microfluidic precipitation was 
assessed by comparing the DSC thermal profiles and XRPD traces of unprocessed (raw 
HC) and processed HC (the powder gathered after centrifugation and drying the 
nanosuspension).  
 
The DSC thermal profiles of raw HC (Figure 4-13) shows a sharp peak at 224°C, 
which corresponds to the melting point of HC. In contrast, this peak disappeared 
completely in the DSC traces of HC NS, suggesting an amorphous state of these 
particles. DSC thermal profile of processed HC shows a glass transition peak at 70°-75° 
C, which is not followed by recrystallization. This is may be attributed to high viscosity 
of the melt or other factors inhibiting molecular motion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-13: DSC thermal profiles of unprocessed (raw) and processed 
hydrocortisone. 
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This finding was confirmed by comparing the XRPD spectra of the processed 
and unprocessed hydrocortisone (Figure 4-14). In contrast of the intense crystalline 
peaks at 2θ of 6, 14.5 and 17, observed in XRD spectrum of unprocessed HC, XRD 
spectrum of HC NS showed almost a smooth line with no characteristic peaks. This 
confirmed the view that the crystalline structure of changed after the process of 
precipitation. 
 
 
 
Figure 4-14: XRPD patterns of unprocessed (raw) and processed hydrocortisone. 
 
 
4.3.5 Physical stability study 
 
Storage stability of nanosuspensions is of great concern, as finely dispersed 
particles in an aqueous phase have a high tendency to agglomerate together leading to 
the formation of larger aggregates. Ostwald ripening presents an additional stability 
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problem. Furthermore, due to the high energy of the amorphous state, particles may 
relax to the lower-free energy crystalline form. The determination of the zeta potential 
of a nanosuspension is useful as it gives an idea about the physical stability of the 
nanosuspension (Patravale et al. 2004). A high value of zeta potential tends to suggest 
that good physical stability will exist. The measured zeta potential of HC NS was found 
to be −18 mV ± 2.84, a value close to the generally regarded value of ±20 mV, required 
for a physically stable nanosuspension stabilized by electrostatic and steric stabilization 
(Jacobs and Muller 2002). After 3 months of storage at room temperature (25 °C), the 
hydrocortisone NS remained homogeneous and no particle settling was observed. The 
mean particle size and PDI increased to 687 nm and 0.235 respectively (Figure 4-15).  
 
Figure 4-15: Plot representing particle size and polydispersity index (PDI) changes 
with storage time at 25 °C. 
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4.4 Conclusion 
 
Results of Chapter 4 revealed that a hydrocortisone nanosuspension could be 
prepared based on a bottom-up creation using microfluidic reactors. A narrow sized 
hydrocortisone nanosuspension formed of amorphous spherical particles with a mean 
particle size of 500 nm was obtained. A mild tangential flow filtration system was used 
to concentrate the prepared nanosuspension without affecting drug particle size.  The 
produced hydrocortisone nanosuspension remained homogeneous with slight increase 
in mean particle size and polydispersity index over a 3 month period. These results 
open the door for the opportunity to formulate hydrocortisone as nanosuspension for 
drug delivery, e.g. ophthalmic formulation. 
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5  A comparative 
Biopharmaceutics Study of 
Nanoprecipitated and Nano-
milled Hydrocortisone 
Suspensions 
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5.1 Introduction 
 
Nano-drug formulations have been developed to enhance dissolution and 
bioavailability of drugs with poor aqueous solubility (Filippos Kesisoglou et al. 2007). Of 
these various formulations, drug nanosuspensions were found to be effective and 
promising (Hecq et al. 2006 A; Yang et al. 2008; Ganta et al. 2009). Drug 
nanosuspensions are composed of submicron drug particles (amorphous or crystalline) 
suspended in a dispersion medium (mostly water) and stabilized by polymer(s) or 
surfactant(s) (Rabinow 2004). The two approaches of top-down (breaking of large drug 
particles as in milling and homogenization) or bottom-up (building up nanoparticles 
from drug molecules via precipitation) can be used to prepare nanosuspensions (Li et 
al. 2007). As discussed previously, the limitations of top down methods involving high 
energy input, the possibility of contamination, difficulty to produce nanoparticles with 
a size below 100 nm (He et al. 2010), encourage research to consider bottom up 
techniques as alternatives for drug nanonization. However bottom-up techniques, 
such as spray freezing into liquid and supercritical antisolvent precipitation require 
complex operating equipment (Zhao et al. 2007). Accordingly, a strong driver remains 
in finding less complicated techniques for preparing drug nano-sized particles. Particle 
engineering using microfluidic techniques has been successfully applied to 
nanomaterials, and the results shown in Chapter 3 and 4 indicate the potential of this 
methodology for pharmaceutical organic compounds. The specific example of a 
hydrocortisone nanosized suspension has been prepared and characterized. 
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 In conventional eye drops, ocular residence time is short and consequently 
ocular bioavailability is low due to rapid elimination from the corneal surface by the 
lachrymal flow (Nagarwal et al. 2009). Frequent administrations are necessary in order 
to achieve and maintain therapeutic effect. In turn, this may lead to poor patient 
compliance or undesirable side effects due to unwanted systemic drug absorption 
(Séchoy et al. 2000; Gupta et al. 2010). Several approaches such as using viscosity 
imparting agents, penetration enhancers, drug delivery devices, have been proposed 
to improve ocular drug bioavailability. The value of viscosity enhancers may be limited 
because the formulations are still liquid and the drug in solution will be easily removed 
from the eye by its defensive mechanisms. Great care needs to be taken when 
incorporating penetration enhancers due to high sensitivity of the eye tissues to such 
compounds. Local irritation may result from ocular drug delivery devices because they 
must remain at the point of application for several hours (Araújo et al. 2009). Drug 
nanosuspensions have potential benefits in ophthalmic drug delivery and in 
overcoming some of the inherent difficulties detailed above (Sahoo et al. 2008). 
Compared to microsuspensions, nanosuspensions cause less irritation and can be 
sterilized by filtration (Pignatello et al. 2002; Sahoo et al. 2008) 
Hydrocortisone is a widely prescribed steroid to treat various inflammation 
disorders of the eye (Davies et al. 1997). As a poorly soluble drug, it can be 
administered as ocular suspensions or a solution of salt derivatives (Bary et al. 2000). 
However, the low aqueous solubility of the steroid (in suspension form) or poor 
partitioning of the hydrophilic steroid derivative into the lipophilic epithelium (in the 
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case of water-soluble salts) may result, in part, in low corneal permeability and 
bioavailability of topically administered steroids (Bary et al. 2000). 
In this Chapter, the technology of controlled liquid antisolvent precipitation 
using microfluidic reactors is applied to prepare a hydrocortisone nanosuspension 
suitable for ophthalmic delivery. In parallel, for comparative studies, a second 
hydrocortisone nanosuspension is prepared by wet milling, as a top down method. The 
nanosuspensions produced were characterized for particle size, shape, and 
crystallinity. The in vivo intraocular bioavailability of these nanosuspensions, compared 
to a solution dosage form, has also assessed in rabbits.  
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5.2 ExperimentalMaterials 
 
Hydrocortisone, absolute ethanol, water (see section 2.2.1). 
Hydroxypropylmethylcellulose, HPMC (6 cp, 2% in H2O) and Kollidon
© 30 (PVP K30) 
(see section 4.2.1). Sodium chloride and tween 80 were purchased from Fisher 
Scientific Ltd (Loughborough, UK). Potassium dihydrogen orthophosphate and 
disodium hydrogen phosphate were purchased from BDH (Poole, UK).  
 
5.2.2  Preparation of nanosuspensions 
 
5.2.2.1 Bottom-up (microfluidic nanoprecipitation) 
 
A hydrocortisone nanosuspension (HC NS) was prepared using a microfluidic 
nanoprecipitation process according to the method described in Chapter 4 with a 
modification. All solutions were filtered through 0.2 µm filters (Whatman, Maidstone, 
England) before use. The organic phase containing HC (12.5 mg/ml) and aqueous 
phase containing stabilizers (0.2% w/v, PVP + 0.5% w/v HPMC, 0.1 % w/v Tween 80 ) 
were mixed in a microfluidic reactor (10° inlet angle and 0.5 ml internal diameter) at a 
flow rate 1:2.5 ml/min, respectively using two digitally controlled syringe pumps. The 
dispersion produced was introduced to 20 ml of saline phosphate buffer solution with 
stabilizers (0.2%, w/v, PVP + 0.5%, w/v, HPMC, 0.1 %, w/v Tween 80) with sonication 
(Decon, Ultrasonics Ltd, Sussex, England) (Figure 5-1). Residues of ethanol were 
evaporated by keeping under vacuum (-635 mm Hg) at room temperature (25 °C) for 
2-3 hours. 
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Figure 5-1: Preparation of  hydrocortisone nanosuspension by bottom up process. 
 
 
5.2.2.2 Hydrocortisone nanosuspension by top-down procedure (milling) 
 
The top-down nanonization was performed by a media wet milling process. A 
250 ml solution of isotonic phosphate buffer (pH 6.8) containing stabilizers (0.2 %, w/v 
PVP, and 0.5, w/v % HPMC, 0.2 % Tween 80) was firstly prepared. HC powder (2%, w/v) 
was then finely dispersed in the solution with the aid of sonication (Decon, Ultrasonics 
Ltd, England) for 5 minutes. The size reduction process was performed in a milling 
apparatus (DM100 processing machine, model no.: BK-T-1M, Dena Systems BK Ltd, 
England) filled with a medium of zirconium beads (size = 0.5mm). Particle size 
reduction was monitored by taking samples at different time intervals during the 
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process. The final formulation of HC NS, 0.1% (wlv), was prepared by taking a 
calculated amount of the milled nanosuspension and diluted appropriately with the 
isotonic phosphate buffer solution with stabilizers.  
 
5.2.3 Hydrocortisone solution 
 
The solution eye drop of HC was prepared by dissolving 0.1 g of the drug in a 
few drops of propylene glycol and diluting to 100 ml with isotonic phosphate buffer 
(pH 6.8) containing 0.5% (w/v) hydroxypropylmethylcellulose, 0.2%  (w/v) PVP and 0.2 
% (w/v) Tween 80. 
 
5.2.4 Characterization of nanosuspensions 
 
The particle size and zeta potential of the nanosuspensions were determined 
by the methods of photon correlation spectroscopy and electrophoretic mobility, 
respectively, using a Zetasizer Nano® instrument (Malvern Instruments, UK). The 
morphology of the drug particles was examined using scanning electron microscopy 
(Quanta 400 SEM, FEI Company, Cambridge, UK). Samples of precipitated HC NS were 
first mounted onto the surface of a copper grid, dried at ambient temperature and 
stained using 2% uranyl acetate solution. The HC content in the tested formulations 
was assayed spectrophotometrically (V-530 UV-Vis spectrophotometer, Jasco, Japan) 
at wavelength of 247 nm. The apparent viscosity of the tested formulations was 
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measured using a cone and plate shear rheometer (Anton Paar MCR 501, Germany) at 
25 °C using a 1 ml aliquot of the sample. 
 
5.2.5 Evaluation of crystallinity of drug particles 
 
Hydrocortisone solid samples were collected from the nanosuspensions by 
centrifugation (Avanti ultracentrifuge, Beckmann, USA) operating at 4°C and rotation 
speed of 25000 rpm for 30 minutes. The  residues were gently dried in a heated 
vacuum desiccator at of 35 °C and -25 inch Hg. X-ray powder diffraction spectra of the 
dried HC samples were obtained using a Siemens D5000 diffractometer (Siemens, 
Germany), using Cu Kα radiation (λ = 1.5418 Å). Drug samples were scanned over an 
angular range of 2θ (2–50°), with a step size of 0.05° and a count time of 3 s per step. 
Powder samples were rotated at 30 rpm during analyses. Differential scanning 
calorimetric (DSC) analysis was performed (TA Q2000, USA) with samples of HC 
examined at a scanning rate of 10 °C/min under nitrogen gas flow. The temperature 
for the scan ranged from 30 to 250 °C. The crystallinity index (Xcr) was calculated 
according to equation (13) (Niwa et al. 2010):   
         
𝑿𝒄𝒓 = � 𝚫𝑯𝚫𝑯𝝄� × 𝟏𝟎𝟎           Equation 13  
 
 
 
 
 
Where: 
 ΔH: the heat of fusion of  
the wet-milled crystals 
Δ Ho:  the heat of fusion of  
the unprocessed crystals 
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5.2.6 Ocular bioavailability 
 
Drug ocular bioavailability studies were carried out using five adult male 
normotensive albino rabbits, each weighing between 1.8 - 2.2 Kg. The animal 
study was performed according to the local agreement and permission provided by the 
Egyptian ministry of higher education to universities performing research.  
The rabbits were provided with food and water ad libitum in a temperature-
controlled room (25 °C). A Schiotz tonometer (Reister, Germany) was used to measure 
intra ocular pressure (IOP) after instilling one drop of a local anaesthetic (tetracaine, 
0.5% w/v) into the eye to be tested. A dose of fifty microliters from each formulation 
was instilled from a syringe in the lower conjunctival sac. The IOP was measured 
immediately prior to drug administration and then following administration at 
different time intervals for up to 9 hours. The IOP measurements were carried out 
completely by the same operator using the same tonometer. A two-day washout 
period, at least, was allowed between administration of different formulations and the 
normal baseline of each animal was established before testing the next formulation. 
The change in IOP (ΔIOP) was determined according to equation (14):  
% ∆ 𝑰𝑶𝑷 = (𝑰𝑶𝑷𝒑𝒐𝒔𝒕 𝒅𝒐𝒔𝒊𝒏𝒈−𝑰𝑶𝑷𝒑𝒓𝒆𝒅𝒐𝒔𝒊𝒏𝒈)
𝑰𝑶𝑷𝒑𝒓𝒆𝒅𝒐𝒔𝒊𝒏𝒈
 × 𝟏𝟎𝟎              Equation 14 
 
The pharmacodynamic parameters used to evaluate the efficiency of the 
different formulations included, time for maximum response to achieve peak ΔIOP 
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(Tmax), the peak ΔIOP (ΔIOP max), and the area under the ΔIOP-time-curve (AUC0→9 h), 
and mean residence time (MRT).  
 
5.2.7 Statistical analysis 
 
Statistical differences of the obtained results were studied using one-way 
analysis of variance (ANOVA), followed by the least significant difference test (LSD). 
This statistical analysis was computed using SPSS® software (SPSS Inc., Chicago, USA).  
 
5.2.8 Physical stability 
 
Physical stability of the prepared HC nanosuspensions was investigated at 25°C. 
The changes in appearance and PCS particle size were recorded over a 2 month period.  
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5.3 Results and discussion 
 
5.3.1 Nanosuspension preparation 
 
5.3.1.1 Bottom-up microfluidic nanoprecipitation 
 
As mentioned previously in Chapter 4, the nanoprecipitation process is initiated 
by mixing of the antisolvent and the hydrocortisone solution streams, so that drug 
supersaturation, nucleation and particle growth occurs in a central diffusion layer of 
the microreactors (Karnik et al. 2008). The conclusion from Chapter 3 indicated that 
the antisolvent (water) flow rate can be adjusted to direct the particle size of the final 
product. Pushing the antisolvent flow rate at a higher value than drug solution was 
found to induce higher supersaturation and drug nucleation and result in reducing the 
size of generated particles. Moreover, particle growth could decrease with increasing 
antisolvent rate due to reducing the availability of solute around the growing drug 
particles (Zhao et al. 2007).  
 
The generated HC particles were then introduced to an aqueous solution of 
stabilizers under sonication to complete preparation step. Preliminary (unreported) 
experiments showed that mixing under sonication produces smaller and more uniform 
HC particles compared to mixing by mechanical stirrers. Ultrasound ensures efficient 
mixing when solvent was added to the antisolvent. Sonication also helps to de-
aggregate particles.   A HC NS (0.1 % w/v) with mean particle size of 295 ± 32 nm 
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(Figure 5-2) was generated. The polydispersity index (PDI) was found to be 0.21 ± 
0.026 suggesting a good distribution profile (Patravale et al. 2004).  
 
 
 
  
 
 
 
 
 
Figure 5-2:  Particle size distribution of hydrocortisone NS prepared by microfluidic 
nanoprecipitation. 
 
5.3.1.2 Top-down (milling) 
 
In the wet milling process, the high energy, shear forces and turbulent 
environment generated as a result of the impaction of the grinding media with the 
drug particles provides sufficient energy to break the drug microparticles into 
nanoparticles (Merisko-Liversidge et al. 2003). An HC NS was successfully prepared by 
milling a slurry of HC and stabilizers, reaching a particle size of approximately 300 nm 
after 105 min (Figure 5-3). Changes in PCS diameter (Z-AVE) and polydispersity index 
(PDI) of hydrocortisone as a function of processing time are shown in Figure 5-4. The 
PCS diameter decreased to approximately 400 nm after 45 minutes processing time 
with reduced change in size observed between 45 – 105 minutes. For all samples taken 
at different milling times, the PDI value remains below the value of 0.25 (final PDI = 
0.18) indicating a narrow size distribution of the milled HC NS. 
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Figure 5-3: Particle size distribution of hydrocortisone nanosuspension prepared by 
wet milling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4: Changes of particle size and polydispersity index of hydrocortisone 
nanosuspension with miling time. 
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5.3.2 Particle morphology 
 
Figure 5-5 shows the visual appearance of the hydrocortisone nanosuspensions 
compared to a suspension of unprocessed HC and an HC solution of the same 
concentration. The nanosuspensions shown are bluish and transparent relative to the 
coarse suspension, indicating a nanosized state of HC particles (Kamiya et al. 2009). 
In addition to particle size analysis, the SEM micrographs (Figure 5-6) confirmed 
that both the milling and microfluidic nanoprecipitation processes are effective in 
converting the original HC particles into the submicron range. Particles of unprocessed 
HC exhibited larger particles of irregular shapes and lacking size uniformity. The wet-
milled HC was composed of fractured, irregular shaped particles with various sizes. In 
contrast, particles generated by nanoprecipitation using the microreactors were 
regular, round-shaped particles and more uniform in size and shape.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5-5: Appearance of hydrocortisone nanosuspensions (milled, B and 
precipitated, C) compared to solution (D) and coarse suspension (A) of the same 
concentration (0.1 %, w/v). 
A B C D 
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Figure 5-6: SEM micrographs of different hydrocortisone particles; A: unprocessed 
HC, B: milled HC, C: precipitated HC. 
A 
C 
B 
B 
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5.3.3 Particle crystallinity 
 
The crystalline state of the precipitated HC NS and the wet-milled HC NS was 
evaluated by comparing their XRPD spectra to the XRPD profile of unprocessed HC 
(Figure 5-7). Intense peaks were observed at 2θ of 14.5°, 16° and 17° in the spectrum 
of unprocessed HC indicating a highly crystalline structure. The peaks of lower 
magnitude in the XRPD of the wet milled HC NS were consistent with the XRPD pattern 
of unprocessed HC with the reduced peaks intensities attributed to the interference 
with the crystalline state of bulk drug as a result of the high-shear particle size 
reduction process (Deng et al. 2008; Xia et al. 2010). Increased baseline noise is 
observed possibly due to the amorphous HPMC layer on the surface of the dried drug 
particles (Steckel et al. 2003).  The characteristic peaks of crystalline HC were mostly 
absent for the precipitated HC NS samples (Figure 5-7), suggesting predominance of 
low ordered or amorphous state in these HC particles. 
  
 
 
 
 
 
 
 
Figure 5-7: XRPD patterns of hydrocortisone particles. 
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Further analysis by DSC (Figure 5-8) supports the hypothesis that HC 
crystallinity was maintained after milling. The thermal profile of the wet milled HC NS 
shows an endothermic melting peak similar to the unprocessed HC. However, the 
melting peak of the milled HC was not as sharp as unprocessed HC and slightly shifted 
to a lower temperature event (Yang et al. 2010). The relative ratio of heat of fusion 
against the original bulk (the crystallinity index, Xcr) of the milled HC particles 
decreased to a value of 0.763:1. The decrease in the heat of fusion and Xcr are also 
indicative of a decrease in crystallinity (Niwa et al. 2010). Being a high-energy process, 
milling may cause disorders and cleavage of the crystal lattice at the weakest sites 
(Steckel et al. 2003).  However, for the precipitated HC NS, the crystalline structure has 
been dramatically reduced or lost after nanoprecipitation and drying as reflected by 
the disappearance of the melting endothermic peak. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-8: DSC thermal profiles of hydrocortisone particles. 
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5.3.4 Ocular bioavailability 
 
The ocular hypertensive response to corticosteroids is well established for all 
routes of drug administration including topical, inhaled or systemic (Opatowsky et al. 
1995; Law and Lee 2008). The exact mechanism by which corticosteroid-induced 
elevation in IOP is not well recognized but may be due to decreasing aqueous out flow 
(Buggage 2003). Such corticosteroid-induced increases in IOP can be measured 
accurately by the Schiotz tonometer and consequently used to evaluate their effects 
(Kassem et al. 1994; Safwat et al. 1994; Kassem et al. 2007). 
Results of IOP measurements are presented in Figure 5-9. The baseline IOP of 
the rabbits measured and used was 12.2 mm Hg.  Application of different HC 
formulations produced a remarkable increase of IOP in normotensive rabbits reaching 
peak levels. Then with time the IOP slowly returned to the pretreatment values. For HC 
solution, the maximal increase in IOP effect of 52.16 ± 9.8 % was achieved at 0.5 h 
after instillation of the formulation, whereas, the values of % ∆ IOP max   for the 
precipitated and milled NS were 57.60 ± 13.1 %, 48.63 ± 14.8 %, respectively, and were 
achieved at 1 and 0.5 h, respectively. These results indicate that there is no major 
difference in onset of drug action between drug solution and the two 
nanosuspensions. With nanoparticles of HC, the solid surface area, saturation solubility 
and consequent drug dissolution is expected to be increased (Junghanns and Muller 
2008), providing sufficient initial drug concentration for absorption, triggering the 
measured effect.  
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Figure 5-9: Changes in intraocular pressure (IOP) of rabbits eyes following 
administration of hydrocortisone solution and nanosuspensions produced by milling 
and precipitation.  
 
 
Regarding the duration of drug action, it is clear from Figure 5-9, that drug 
action was sustained up to 8-9 hrs (for the HC nanosuspensions) compared to 4-5 hrs 
for the drug solution. Being in suspension form, the HC nano-sized particles act as a 
reservoir to replenish the utilized drug (absorbed and/or eliminated).  A non significant 
increase in IOP was noticed with the milled HC NS compared to the precipitated HC NS. 
Generally, crystalline nano-sized particles exhibit longer dissolution times compared to 
their amorphous counterparts (Yang et al. 2010). The extended HC duration was also 
reflected by the higher values of MRT for the precipitated and milled NS, 2.23 ± 0.07 h, 
Time (h) 
%
 C
ha
ng
e 
in
 IO
P 
                                                                                                         Drug Nanosizing Using Microfluidic Reactors       
  
140 
 
 
2.24 ± 0.10 h, respectively, which are significantly (P < 0.05) different from the drug 
solution, 1.68 ± 0.08 h, (Table 5-I). 
 
Table 5-I:  Pharmacodynamic and pharmacokinetic parameters following ocular 
administration of hydrocortisone solution, precipitated and milled hydrocortisone 
nanosuspensions (mean ± SD).  
 
Formulation T max (hr) 
% ∆ IOP max 
(mm Hg) AUC0-9hr 
MRT 
(hr) 
HC Solution 0.5 52.16 ± 9.8 15.86 ± 2.70 1.68 ± 0.08 
HC NS nanoprecipitation 1 48.63 ± 14.8 28.06 ± 4.08 2.23 ± 0.07 
HC NS milled 0.5 57.60 ± 13.1 30.95 ± 2.2 2.24 ± 0.10 
 
 
The nanosuspension formulations produced AUC values of 28.06 ± 4.08 and 
30.95 ± 2.20 for the precipitated and milled NS, respectively, that are significantly 
higher (P < 0.01) than that obtained after the instillation of the HC solution 15.86 ± 
2.70 (Table 5-I). This result demonstrates that higher bioavailability was obtained using 
nanosuspension formulations. Whilst a small increase was observed in the AUC for the 
milled HC NS, however this increase was found to be insignificant (P > 0.05).   
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The formulations had approximately equal viscosities (1.93 ± 0.01 cp for drug 
solution, 1.77 ± 0.01 cp for precipitated NS and 1.65 ± 0.01 cp for milled NS). Thus the 
improved bioavailability and prolonged drug effect may only be attributed to the 
nanoparticulate nature of the drug. With the drug in solution form, drug action can be 
reduced by rapid drug removal from the cornea surface after administration. 
Conversely, hydrocortisone was retained longer in the ocular site as nanocrystals and 
the progressively dissolved amounts of drug could be available for the immediate and 
subsequent trans-corneal absorption (Pignatello et al. 2002). In addition, drug 
nanoparticles adhere to biological membranes (e.g. corneal adhesion), a property that 
may contribute in sustaining drug action (Ravichandran 2009).  Higher peaks of IOP 
(Figure 9) may be linked to the difference in affinity of drug particles to corneal 
membrane due to dissimilarity of their surfaces.    
 
5.3.5 Physical stability 
 
Physical stability is a crucial issue in formulating drug nanosuspensions. During 
the manufacture of a nanosuspension, additional surface area and interfaces are 
created together with an increase in the free energy of the system (Van Eerdenbrugh 
et al. 2008). Therefore, the nanosuspensions formed are thermodynamically unstable 
with a tendency to agglomerate in order to minimize total energy. Moreover, Ostwald 
ripening (the process of growing of larger particles on the expense of smaller particles 
due to enhanced solubility of the latter) may contribute to nanosuspension instability. 
Changes in the particle size of the prepared nanosuspensions were investigated as a 
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function of storage time at room temperature (25 °C) (Figure 5-10). In both 
nanosuspensions, a combined stabilizing effect was achieved using a mixture of 
stabilizers (0.5% HPMC + 0.2% PVP + 0.1 % Tween 80), which are likely to be adsorbed 
to some extent onto the surfaces of the generated nanosized particles. The stabilizers 
can be adsorbed onto the surfaces of the generated nanosized particles. The measured 
values of zeta potential were – 2.09 ± 0.16 and -1.47 ± 0.40 for the milled HC NS and 
precipitated HC NS, respectively. Small values of zeta potential (close to zero) may be 
indicative of complete stabilizer coverage on the drug particles and may help to 
explain the enhanced nanosuspension stability on storage (Verma et al. 2009). 
However, this was only true for the milled HC NS and not for the precipitated HC NS.  
Storage at room temperature for two months, the milled HC NS demonstrated 
superior stability with no discernable changes in PCS size (initially, 298 nm) (Figure 5-
10). On the other hand, the PCS size of the microfluidic precipitated HC NS increased to 
440 nm, compared to the initial size of 295 nm. This overall size profile may indicate 
post precipitation growth and/or particle aggregation, which is likely more associated 
with the amorphous nature of precipitated particles.  Compared to the crystalline 
counterpart, solubility is expected to be enhanced for amorphous nanoparticles 
(Lindfors et al. 2006; Lindfors et al. 2007; Junghanns and Muller 2008) giving a greater 
potential for Ostwald ripening in the precipitated nanosuspension.  
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Figure 5-10: Change of particle size of the prepared hydrocortisone nanosuspensions 
with storage time at 25° C.  
 
 
 
5.4 Conclusion 
 
Hydrocortisone nanosuspensions for ocular drug delivery with a mean PCS 
diameter of approximately 300 nm were successfully prepared using top-down (wet 
milling) and bottom-up (microfluidic nanoprecipitation) procedures. The 
nanosuspensions demonstrated sustained therapeutic effect as assessed by IOP in 
rabbits, and enhanced bioavailabilities compared to the hydrocortisone solution.  
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6  Development and in-vitro 
Evaluation of Microfluidic 
Nanoprecipitated Budesonide 
Suspensions for Pulmonary 
Delivery 
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6.1 Introduction 
 
6.1.1 Pulmonary drug delivery 
 
The pulmonary route (Figure 6-1), especially the lungs, has been utilised as a 
suitable avenue for drug delivery for thousands of years. Ancient Egyptians and Indians 
smoked herbal preparations like datura and hyoscyamus; which contain alkaloids with 
anticholinergic bronchodilating properties (Anderson 2005). In the 19th and early 20th 
centuries, stramonium powder mixed with tobacco was used by asthmatics to treat 
the symptoms of their disease (Labiris and Dolovich 2003, B). 
 
 
Figure 6-1: Schematic of pulmonary system and deposition of drug particles. 
 
Source (Hu et al. 2008). 
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Inhalation of drugs can be used in the treatment of local respiratory diseases 
such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, chronic 
bronchitis, chronic pulmonary infections or lung cancer. Advantages of inhaled drugs 
over systemic delivery of these drugs include (Labiris and Dolovich 2003, A): 
• Delivering high drug concentrations directly to the site of action.    
• Reducing the risk of systemic side effects (for example, minimize the 
problems associated with oral steroids, such as adrenal suppression, 
electrolyte imbalance and muscle weakness). 
• Rapid clinical response. 
• Bypassing the barriers to therapeutic efficacy, such as poor 
gastrointestinal absorption and first-pass metabolism in the liver. 
• Decreasing the dose required to achieve a similar or superior 
therapeutic effect. For example, the amount of drug administered to 
patients is 10–20% of the amount administered by the oral route 
(Jaspart et al. 2007). 
 
Recently, pulmonary drug delivery has been increasingly recognised as an 
efficient route for systemic delivery of therapeutic agents, especially for drugs with 
proteinous nature like insulin, interferons and growth hormones (Vanbever 2005). 
Delivering therapeutic agents to the lung for systemic action offers several advantages 
compared to as intravenous, oral or other drug delivery systems. These advantages 
include (Labiris and Dolovich 2003, A): 
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• A painless, non invasive, needle free, delivery system and this can 
improve patient comfort and compliance.  
• Suitability for a wide range of substances from small molecules to very 
large proteins. 
• Massive absorptive area (80 - 140 m2) and thin permeable membrane 
(0.1 – 0.2 µm thickness) in the alveolar region. The distance between 
surface of epithelial tissue and blood in the alveolar area is between 0.5 
µm and 1.0 µm (for comparison, distance between mucous surface and 
blood is 30 µm – 40 µm) (Scheuch et al. 2006). 
• Relatively low local metabolic activity as well as a lack of first-pass 
hepatic metabolism. 
• Reproducible absorption kinetics. Pulmonary delivery is independent of 
dietary complications, extracellular enzymes and interpatient metabolic 
differences that affect gastrointestinal absorption. 
• Independent of dietary interferences as in oral administration.  
• Relatively less enzymatic deactivation and good blood supply (Sakagami 
2006). 
The mechanisms for absorption of macromolecules by the healthy lung are still 
poorly understood, but the proposed mechanisms include transcytosis, paracellular 
absorption and absorption via large transitory pores in the epithelium left by injured 
cells (Patton 1996). 
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Although the pulmonary route of drug delivery offers advantages, it also 
presents some limitations (American Academy of Pediatrics 1997; Jain 2008): 
• Local toxic effects of the drug. 
•  Local or systemic toxic effects may result from propellants, 
preservatives, or carriers.  
• Mucociliary transport may affect drug residence time. 
• A percentage of 10-40 % of drug leaves inhalation device can deposit in 
the lungs using conventional devices. 
• Pulmonary drug delivery may be limited due to low aqueous solubility 
and slow drug dissolution (Arun et al. 2008). 
 
6.1.2 Delivery devices 
 
Inhaled drug delivery systems can be categorised into 3 principal classes; 
nebulizers, pressurised metered dose inhalers (MDIs) and dry powder inhalers (DPIs). 
This classification is based on the physical states of dispersed phase and continuous 
medium, and within each class further differentiation is based on metering, the means 
of dispersion, or design (Telko and Hickey 2005).   
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6.1.2.1 Nebulizers 
 
Nebulizers differ distinctly from MDIs and DPIs in that the drug is dissolved or 
suspended a polar liquid, usually water (Taylor 2002). Nebulizers can deliver large 
volumes of drug formulations (solutions or suspensions) for inhalation. They can be 
used to deliver drugs, such as proteins, where the therapeutic dose is too large for 
delivery by either MDIs or DPIs (Taylor and McCallion 1997). Basically, there are two 
types of nebulizers, jet and ultrasonic nebulizers. In jet nebulizers (Figure 6-2A), a 
compressed gas (air or oxygen) passes through a narrow orifice and creates an area of 
low pressure at the outlet of the adjacent liquid feed tube. As results, the drug solution 
will be drawn up from the fluid reservoir and split into droplets in the gas stream. In 
ultrasonic nebulizers (Figure 6-2B), a piezoelectric crystal vibrating at a high frequency 
(usually 1-3 MHz) is used to generate a fountain of liquid in the nebulizer chamber; the 
higher the frequency, the smaller the droplet produced (Labiris and Dolovich 2003, B).  
 
 
Figure 6-2: Schematic diagram of nebulizers   A: jet nebulizer   B: ultrasonic nebulizer.  
 
Source  A (Le Brun et al. 2000),  B (O'Callaghan and Barry 1997). 
A B 
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6.1.2.2 Metered dose inhalers (MDIs) 
 
MDIs are the most commonly used inhalation delivery devices. MDIs contain 
the pharmaceutically active ingredient, dissolved or suspended in a propellant system, 
which contains at least one liquefied gas, propellant, with other additives (e.g.  
surfactants) in a pressurised container (canister) that is sealed with a metering valve 
(Figure 6-3). Upon actuation of the valve, a metered dose of the medicament in the 
form of an aerosol spray, will be expelled, and directed by a suitable adaptor/actuator 
for administration via oral or nasal inhalation (Shoyele and Slowey 2006). The MDI 
emits a drug aerosol driven by a propellant, such as chlorofluorocarbon (CFC), or more 
recently ozone-friendly propellants as hydroflouroalkanes (HFA-134a and HFA-227). 
 
 
 
 
                           
 
Figure 6-3: Schematic of typical pressurized metered-dose inhaler with the key 
component parts.  
Source (Newman 2005). 
                                                                                                         Drug Nanosizing Using Microfluidic Reactors       
  
151 
 
 
6.1.2.3 Dry powder inhalers (DPIs) 
 
DPIs have been developed as an alternative to pMDIs possessing a green 
advantage in that they are propellant free. Most DPIs contain micronized drug blended 
with larger carrier particles to prevent aggregation and improve flowability. In passive 
inhalers, patient’s inspiratory flow creates shear and turbulence in the device, the 
static powder blend is fluidized and enters the patient’s airways. Then the drug 
particles separate from the carrier particles and are carried deeper into the lung. 
Because of its large size, the larger carrier particles impact in the oropharynx and are 
cleared (Figure 6-4). In addition to breath-activated DPIs, several power-assisted 
devices (pneumatic, impact force, and vibratory) have been developed or are currently 
under development (Taylor 2002). 
 
 
 
 
 
Figure 6-4: Principle of dry powder inhaler design. 
Source (Taylor 2002). 
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6.1.3 Pulmonary deposition of aerosols  
 
Suitable particle size is a major prerequisite for a successful pulmonary drug 
application. The sizes of particles that are used in inhalation therapy are commonly 
expressed by the aerodynamic particle diameter (dae), which is equivalent diameter of 
a sphere with a density of 1g/cm3 (𝜌𝜊) (that has the same aerodynamic behaviour as 
the particle being measured (de Boer et al. 2002).  
 
   
𝒅𝒅𝒆 = 𝒅 � 𝝆𝝆𝝄 𝒙     Equation 15 
 
 
 
For successful deposition, it is necessary for the particles to be small enough to 
avoid deposition by impaction in the upper respiratory tract and enable them to 
negotiate the transitions of the upper airways and pass through the mouth, larynx, 
pharynx and lower airways.  Simultaneously, drug particles should be large enough (or 
having sufficient inertia) to avoid exhalation. Accordingly, it is widely agreed that the 
suitable particle size for should be less than 5 µm. The lower limit varies in the 
scientific literature, 0.3 µm (Schiewe and Ziereberg 2003), 0.5 µm (Timsina et al. 1994) 
or 1 µm (Kim and Shing 2007). 
The three principal modes leading to pulmonary deposition are inertial 
impaction, sedimentation, and diffusion. The inertial impaction occurs when particles 
where: 
 
 d   :  geometric diameter of the particle. 
 ρ  : the particle density  
 χ  : the particle dynamic shape factor  
       denoting deviation from sphericity, 
       which is 1 for a sphere. 
 
                                                                                                         Drug Nanosizing Using Microfluidic Reactors       
  
153 
 
 
possess a certain mass and velocity during their passage through the oropharynx and 
large conducting airways. It refers to the process where upon contact with objects, 
particles deviate from the gas streamline that ultimately allows for deposition of 
particles on the walls of the surrounding environment. Particles larger than 5 µm 
deposit primarily by inertial impaction while particles between (0.5-3 µm) deposit 
primarily by gravitational sedimentation (Gill et al. 2007). For particles less than 0.5 µm 
deposition by diffusion, based on Brownian motion, occurs (Scheuch et al. 2006), or in 
some cases such small particles do not deposit and exhaled. 
Despite being a time-consuming analytical method, impactors have been 
widely employed for aerodynamic diameter characterization (Pilcer et al. 2008). 
Separation in cascade impactors is based on the principle of inertial impaction (i.e. 
depending on the differences in inertia - a function of particle size and velocity). 
Cascade impactors are composed of a series of stages each built up of a plate (with 
specific nozzle arrangement) and collection surface. Inside the impactor, the drawn 
aerosol flows sequentially through a number of stages; nozzle size and total nozzle 
area decrease with stage number. As particles pass through the nozzles (see Figure 6-
5), they either remain entrained in the air stream, which is directed through a right 
angle at the exit of the nozzle, or impact on the collection surface. Particles with 
sufficient inertia are collected, with the rest passing onto the next stage. Each stage of 
the impactor is therefore associated with a cut-off diameter which defines the size of 
retained particles on the collection surface of that stage (Copley 2007).  
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Figure 6-5: Flow in a cascade impactor. 
Source   (Copley 2010). 
 
 
 
6.2 Aim of work in Chapter 6 
 
Many of the drugs intended for pulmonary delivery are poorly soluble in 
aqueous solution. Of these drugs, inhaled corticosteroids such as budesonide are 
recognized as standard therapy for paediatric and adult asthma. Delivering sufficient 
concentrations of inhaled corticosteroids to the lower respiratory tract is a challenge 
(Giraud and Roche 2002). Budesonide is available in MDI and DPI presentations. 
However for certain population groups (e.g. paediatric group) such formulations are 
unsuitable. As a result, budesonide is also commercially available as a suspension for 
nebulization. There are some limitations associated with the use of budesonide 
suspension in this formulation, including lengthy treatment time and difficulty of 
effective administration using faster nebulizers such as ultrasonic or next generation 
nebulizers. In addition, relatively large drug micron-sized particles carried in large 
droplets results in drug being deposited in the back of the mouth and throat, which 
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may lead to localized immune suppression and local side effects, such as oral yeast 
infections, and remain available for systemic absorption (and hence adverse effects) 
without providing therapeutic benefit (Shrewsbury et al. 2009). 
 
In this Chapter, it is hypothesized that nanosizing budesonide particles can be 
effective in overcoming the above mentioned limitations of nebulized 
microsuspensions. Accordingly, the research has been directed to prepare nano-
budesonide formulations suitable for pulmonary administration based on precipitation 
within microfluidic reactors. Furthermore, the work has considered the impact of 
budesonide nanonization by this technique on aerosolization behaviour compared to 
that obtained from a commercial budesonide microsuspension (Pulmicort® Respules®). 
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6.3 Experimental 
6.3.1 Materials  
 
• Micronized budesonide, absolute ethanol (see section 2.2.1).  
•  Polysorbate 80 and sodium chloride, potassium dihydrogen 
orthophosphate and disodium hydrogen phosphate, distilled water (see 
section 5.2.1). 
• Acetonitril (HPLC grade), methanol (HPLC grade), sodium chloride, citric 
acid and sodium citrate were purchased from Fisher Scientific Ltd 
(Loughborough, UK).  
• Pulmicort® Respules® 1 mg/ 2 ml, were purchased from AstraZeneca 
(Loughborough, UK).  
 
6.3.2 Budesonide nanoprecipitation 
 
In preliminary experiments, budesonide nanosuspensions were prepared using 
configured microfluidic reactors (internal diameter 0.5 and 1 mm, fluid inlet angle 10°) 
and the effect of changing antisolvent flow rates on the generated particle size was 
examined. Subsequently, to prepare the tested budesonide nanosuspension 
formulation (budesonide NS), the budesonide solution (3.5 mg/ml) and the aqueous 
phase (citric acid, sodium citrate, sodium chloride and polysorbate 80) were pumped 
for 2 minutes through a microreactor (1mm internal diameter, 10° inlet angle) at flow 
rates 0.5:3.5 ml/min, respectively. The produced dispersion was kept under vacuum 
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for 3-4 hours at room temperature to allow evaporation of ethanol (Verma et al. 
2009). In this way, a budesonide NS (0.5 mg/ml) in saline citrate buffer (pH 4-5) was 
obtained. 
 
6.3.3 Characterization of nanosuspension 
 
The particle size and the zeta potential of the prepared nanosuspension were 
determined by the methods of photon correlation spectroscopy and electrophoretic 
mobility, respectively, using a Zetasizer Nano (Malvern Instruments, UK). The accuracy 
of the instrument was calibrated by a NanosphereTM size standard, 500 nm (Thermo 
Scientific Corporation, USA). A zeta potential transfer standard® -68 mV ± 6.8 (Malvern 
instruments Ltd, UK) was used as a reference in zeta potential measurements. The 
morphology of the budesonide particles was examined using transmission electron 
microscopy (JEM-1200EX, Japan Electron Optics Laboratory Corporation, Japan) or 
scanning electron microscopy (Quanta 400, FEI Company, Cambridge, UK) as described 
in Chapters 4 and 5.  
 
6.3.4 Aerosolization 
 
6.3.4.1 Nebulizer 
 
 
The Sidestream nebulizer (Respironics, UK), an air-jet nebulizer was employed 
in the aerosolization study (Figure 6-6). As shown in Figure 6-6 B, air from the 
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compressor is forced to passes through a small hole (venturi). The negative pressure 
created by rapid expansion of air sucks fluid up the feeding tube system where it is 
atomised. Small aerosol droplets are released continuously from the nebulizer 
chamber, whereas, larger particles impact on baffles and returns for renebulization. 
During expiration, the nebulization process continues to develop aerosol which is 
wasted (O'Callaghan and Barry 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-6: The Sidestream jet nebulizer. 
 
Source B (O'Callaghan and Barry 1997).  
A 
B 
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6.3.4.2 Aerosol output rate 
 
The aerosol output of the tested preparations (budesonide NS and commercial 
budesonide suspension) was determined according to the European Standard (Figure 
6-7) (Boe et al. 2001; Silkstone et al. 2002). The only variation was that amounts of 
budesonide were determined directly instead of using a fluoride tracer. Four ml of the 
tested samples were introduced into the nebulizer chamber of the Sidestream jet 
nebulizer (the Respironics, UK). A breathing simulation machine (Pari GmbH, Germany) 
was set at a sinus flow of 15 breaths per minute with an inspiration: expiration ratio of 
1:1 and a tidal volume of 500 ml. According to the CEN methodology, two electrostatic 
filters (A and B, Pari GmbH, Germany) were used to collect the fractions of dose 
released during the exhalation phase and inhalation phase of the breathing cycle, 
respectively. The nebulization process was stopped one minute after the occurrence of 
sputtering (the point at which the nebulizer stops continuous work) occurred. The 
amounts of budesonide deposited on the filters and remaining in the chamber and T-
piece connector were extracted with methanol/water solution (70:30, v/v), 
appropriately diluted and quantified by high performance liquid chromatography. Four 
determinations were performed for each sample and the mean (SD) was calculated.  
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Figure 6-7: Schematic diagram of aerosol output system. 
 
 
 
6.3.4.3 Aerodynamic diameter 
 
The design of the CEN methodology for the aerodynamic characterization of 
the emitted dose using a low flow Marple 298X Cascade Impactor (Graseby Ltd., UK) is 
presented in Figure 6-8 (Boe et al. 2001; Silkstone et al. 2002).  Stages of the Marple 
298 X cascade impactor from the top to the bottom represent the cut values of 50, 
21.3, 14.8, 9.8, 6.0, 3.5, 1.55, 0.93 and 0.52 µm (Figure 6-9). Amounts (4 ml) of 
budesonide formulations (the nanosuspension and the commercial suspension) were 
filled into the nebulizer chamber. As shown in Figure 6-8, the airflow through the 
Marple cascade impactor (298 X) was set at a continuous flow of 2 L /min while a 
further 13 L /min was drawn from a second pump connected between the cascade 
impactor and the nebulizer. Accordingly, the total airflow drawn across the outlet of 
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the nebulizer was 15 L /min. The vacuum pump operating the impactor was switched 
on 30 seconds before each nebulizer system. Amounts of budesonide deposited onto 
glass filters (Omega speciality instruments, USA) of the separate stages of the impactor 
were extracted by methanol-water solutions and quantified using HPLC. The Copley 
inhaler testing data analysis software (CITDAS, Copley Scientific, UK) was used to 
calculate the mean mass aerodynamic diameter (MMAD), fine particle fraction (FPF), 
i.e. the percentage of particles having an aerodynamic diameter less than 5 µm, and 
geometric standard deviation (GSD).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-8: Schematic diagram aerodynamic size measurement. 
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Figure 6-9: The Marple 298X cascade impactor. 
 
 
6.3.5 HPLC analysis of budesonide   
 
The budesonide of the samples was quantified using a validated HPLC analysis 
(Amani 2008; Almeziny 2009). The HPLC system involved a stationary phase column of 
25 cm x 4.6 mm, 5 µ Allsphere ODS-2 C18, an HP 1050 pump, an HP 1050 autosampler 
injector with a 100 µl loop, an HP 1050 UV-vis detector (Hewlett- Packard GmbH, 
Germany) and Kontron data system 450-MT2. The mobile phase consisted of 
acetonitrile /phosphate buffer (having 0.025 M of KH2PO4 and Na2HPO4 each) in a 
ratio of 45/55, respectively, and pH 3.5. Flow rate was 1 ml/min and wavelength was 
set at 240 nm. Experiments were performed at ambient temperature. Two injections 
of 100 µl were used for each solution.  
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6.3.6 Statistical analysis 
 
A paired t-test was used to evaluate the differences between the means of two 
groups. P-values less than 0.05 were considered as statistically significant. 
 
6.3.7 Physical stability 
 
In order to check physical stability of budesonide NS, particle size of the 
prepared budesonide NS, kept in glass containers at 4° C and at room temperature, 25 
°C, was monitored for two weeks.  
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6.4 Results and discussion 
 
6.4.1 Particle size analysis and physical appearance of the suspensions 
 
Preliminary experiments showed that budesonide nanosuspensions (average 
particle size range 186 to 673 nm) with narrow size distribution (polydispersity index 
0.06 to 0.22) were prepared using different microreactors under different processing 
conditions. Results of microfluidic nanoprecipitation of budesonide, similar to 
prednisolone and hydrocortisone, showed that increasing the antisolvent flow rate, 
had a major effect in decreasing size of generated drug particles (see Figure 6-10).  
 
Figure 6-10: Effect of change of flow rates in microreactors on drug particle size. 
(Drug saturation level 5 mg/ml, using a microreactor of 10° inlet angle, 1 mm 
diameter). 
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The physical appearances of the tested preparations, namely, budesonide NS 
and the commercial microsuspension are shown in Figure 6-11, where the 
nanosuspension appears translucent and less opaque than the microsuspension, 
indicating a nanosized state of budesonide particles in the nanosuspension.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-11: Physical appearance of A: budesonide nanosuspension, immediately 
after preparation, and B. The marketed microsuspension. 
 
 
PSC analysis of the budesonide NS showed that the mean particle size was 190 
± 6 nm and PDI was 0.15 (Figure 6-12) whereas, the mean particle size of the marketed 
suspension was 3815 ± 26 and PI was 0.2 (Figure 6-13). Previous reports stated that 
the particle size of budesonide of the marketed suspension was 2-3 µm in diameter 
(Vaghi et al. 2005) or 4400 nm (Kraft et al. 2004), and which is likely to be a micronized 
material.  
 
 
 
A B 
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Figure 6-12: Particle size distribution of the tested budesonide nanosuspension. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-13: Particle size distribution of the tested marketed microsuspension. 
 
 
 
 
6.4.2 Budesonide particle morphology 
 
Micrographs obtained using SEM and TEM showed marked differences 
between budesonide particles. Unprocessed budesonide particles were composed of 
irregular shaped crystals with diameter in the range of 2-10 µm (Figure 6-14, A). After 
B 
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the nanoprecipitation process, budesonide particles appeared to be spherical with 
smooth surfaces (Figures 6-14, B, C). The observed diameter of dried budesonide NS 
was found to be slightly smaller than the hydrodynamic diameter obtained by PCS 
analysis (Aboofazeli et al. 2000). Budesonide particles from the commercial suspension 
were larger with sizes of 3-4 µm (Figure 6 -14, D). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-14: Morphology of different budesonide particles. 
 A. Unprocessed budesonide (SEM, bar = 5 µm), B. Dried nanosuspension (TEM, bar = 
0.5 µm), C. Dried nanosuspension at higher magnification (TEM, bar = 0.2 µm), D. Dried 
marketed microsuspension (SEM, bar = 10 µm). 
A 
D C 
B 
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6.5 Aerosolization study 
6.5.1 Aerosol output 
The results obtained from the PCS analysis showed a 20-fold decrease in the 
particle size of the budesonide NS compared to the corresponding microsuspenison. 
The impact of this difference in drug particle size on lung drug delivery can be shown 
using the following calculation. The number of budesonide particles contained in a 
single aerosol nebulised aqueous droplet can be calculated from the following 
equation (16) (Tam et al. 2008).  
 
       
𝑵𝒑𝒂𝒓𝒕𝒊𝒄𝒍𝒆𝒔
𝑵𝒅𝒓𝒐𝒑𝒔
= 𝒇 𝒓𝒅𝒓𝒐𝒑𝒔𝟑
𝒓𝒑𝒂𝒓𝒕𝒊𝒄𝒍𝒆𝒔
𝟑           Equation 16 
 
 
For example, if the volume fraction, f, of particles in the solvent is 0.01, then 
only approximately 1/100 of 3.8 µm aerosol aqueous droplets will contain a 3.8 µm 
particle. In contrast the same sized aqueous droplet would contain approximately 
eighty 190 nm particles. A previous report showed that budesonide in 
microsuspension is preferentially entrapped within droplets of larger aerodynamic 
diameter (Finlay et al. 1997). Nanosizing increases the number of drug particles which 
in turn is likely lead to greater homogeneity in the number of drug particles included in 
each aerosolized droplet (Figure 6-15). As a result, the rate of drug absorption can be 
enhanced for nanoparticles relative to microparticle dispersions, by promoting more 
uniform drug distribution throughout the alveoli (Yang et al. 2010). 
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      Figure 6-15:  Nanosized drug crystals improve distribution in nebulised aqueous     
        droplets. 
 
 
The results of the aerosol output from this study (see Table 6-I) showed that 
the nebulization time for budesonide NS (12.3 ± 0.37 min) is significantly (P < 0.05) 
shorter than for the microsuspension (14.85 ± 0.36 min). This may be advantageous as 
lengthy treatment times may lead to poor compliance. Moreover, analysis of 
inhalation filters indicated that nearly equal amounts of budesonide were recovered 
from the marketed product and budesonide NS. Also, the amounts of budesonide 
recovered from exhalation filters and remaining in the nebulizer chambers were 
similar for both tested formulations (Table 6-I). 
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Table 6-I:  Nebulization time and mean emitted dose of budesonide in different 
locations of aerosol testing expressed as a percent of the nominal dose from the 
Sidestream jet nebulizers (n = 4 separate doses). 
 
 
Budesonide 
Nanosuspension 
Budesonide 
Microsuspension 
Inhalation Filter 
(%) 
14.24 ± 2.51 14.97 ± 4.3 
Exhalation Filter 
(%) 
14.92 ± 3.21 15.27 ± 4.48 
Chamber 
(%) 
69.33 ± 5.08 68.36 ± 8.95 
Connector 
(%) 
1.49 ± 0.33 1.39 ± 0.20 
Nebulization 
time (min) 
12.30 ± 0.37 14.85 ± 0.36 
 
 
 
6.5.2 Particle size distribution 
 
Figure 6-16 displays the deposition pattern of budesonide NS and the 
commercial microsuspension as quantitated from the different stages of the cascade 
impactor. The mean MMAD value in the microsuspension was significantly (p < 0.05) 
larger than MMAD of budesonide NS (6.2 ± 1.09 µm vs., 3.9 ± 0.48 µm respectively) 
(Table 6-II). Furthermore, the respirable fraction (i.e. the FPF or the percentage less 
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than 5 µm) was significantly smaller (p < 0.05) in the case of the microsuspension 
(38.04 ± 7.81) compared with the budesonide NS (56.88 ± 3.37) (Table 6-II). These data 
indicate better in vitro aerosolization performance for the nanosuspension. As found 
for a nano-salbutamol formulation (Bhavna et al. 2009), a relatively high percentage of 
the respirable dose (i.e. % < 5 µm) for budesonide NS resides in the aerodynamic 
particle size fraction smaller than 0.52 µm. Such particles may be exhaled before they 
deposit in the respiratory airways (Yang et al. 2008). However, it has been reported 
that pulmonary deposition of drug particles is bi-modal, so that particles less than 100 
nm can deposit in the alveolar region of lung by diffusion (Byron 1986; Sung et al. 
2007). 
 
With the two preparations containing nearly equal amount of surfactant, it is 
proposed that the difference in budesonide particle size between the microsuspension 
and budesonide NS is the primary and dominant factor for the difference in in-vitro 
drug disposition between the two preparations.  
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Figure 6-16:   Deposition of budesonide (µg) on each stage of the cascade impactor 
using the CEN method for the budesonide nanosuspension and the marketed 
microsuspension (1 mg in 2ml of budesonide as nominal dose). 
 
 
 
Previous studies of the pharmacokinetics of a nebulized nano-budesonide 
suspension (75-300 nm) in healthy volunteers demonstrated a comparable safety 
profile to Pulmicort® Respules® (Kraft et al. 2004). The data showed that a higher Cmax 
and lower tmax were observed with nanobudesonide product, suggesting a more rapid 
rate of drug delivery of budesonide than with the microsuspension. Here, the results 
showed improvement of in-vitro deposition of budesonide NS over the 
microsuspension formulation. Further in-vivo studies are required to confirm improved 
clinical efficacy. 
 
 
NS 
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Table 6-II: Cascade impaction results of the marketed microsuspension and 
budesonide nanosuspension aerosolized using the Sidestream jet nebulizer. 
 
 
                Preparation 
  Parameter 
Budesonide 
nanosuspension  
Budesonide 
microsuspension 
FPF1 [%] 56.88 (3.37)  38.04 (7.82) 
 MMAD2 (μm) 
 
 3.91 (0.49)  
6.22 (1.09) 
 GSD3 2.86 (0.26)  2.20 (0.30) 
 
1 Fine particle fraction (as % of emitted dose) 
 
2MMAD, Mass median aerodynamic diameter 
3GSD, Geometric standard deviation 
 
6.5.3 Physical stability 
 
The bottom-up created nano-budesonide suspension was prepared containing 
polysorbate 80 as a stabilizer, as found in the tested commercial microsuspension. The 
stabilizing effect of polysorbate 80 comes from its ability to be adsorbed and cover the 
generated particle surfaces (steric effect). For the nanosuspension stored at room 
temperature (25 °C), PCS analyses indicted that larger particles (5067 nm) started to 
appear after 4-5 days of storage. Sample stored at 4°C, was found to be comparatively 
more stable with drug particle size fluctuating between 200-300 nm over a period of 
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10 days (see Figure 6-17). However, the presences of a number of larger drug particles 
together with sedimentation of minute crystals were observed after 10 days of 
storage. Fluctuations in drug particle size could be attributed to the dissolution of drug 
nanoparticles (in case of decreasing particle size) or particle growth due to 
agglomeration and/or Ostwald ripening (in case of increasing particle size) 
(Möschwitzer et al. 2004). The measured zeta potential of budesonide NS using water 
only as antisolvent was – 7.93 ± 0.20 and -2 ± 0.37 with using polysorbate 80. The 
difference in zeta potential values is likely to arise from adsorption of the non-ionic 
stabilizer on drug particles resulting in an increase in the thickness of the diffuse 
double layer and hence a lower zeta potential (Verma et al. 2009).  However, from the 
stability results presented, the polysorbate 80-stabilized NS was only stable for a short 
time which may be linked to incomplete surface coverage as a consequence of the 
large surface area generated after nanoprecipitation, or insufficient robustness of the 
adsorbed layer. A further stability screening study using safe and more effective 
stabilizer (s) is needed.  
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Figure 6-17  Change in particle size and polydispersity index (PDI) of budesonide 
nanosuspension stored at 4 °C. 
 
 
 
 
6.6 Conclusion 
 
The capability of bottom-up prepared budesonide nanosuspensions as 
alternatives to the corresponding microsuspension formulations for delivery to the 
lungs using nebulizers has been demonstrated. The overall results showed similar 
patterns for the in-vitro aerosol output studies. However, the budesonide 
nanosuspension has shown advantages regarding to the aerodynamic droplet size, and 
the nebulization time compared to the budesonide microsuspension formulation. The 
fine particle fraction markedly improved in case of budesonide nanosuspension 
indicating improved in-vitro performance for this formulation. From preliminary 
storage studies, the produced nanosuspension could regarded as physically stable for a 
short term (10 days) if stored at 4 °C. 
0
0.05
0.1
0.15
0.2
0.25
0.3
0
50
100
150
200
250
300
350
0 2 4 6 8 10
Particle 
size 
(nm) 
PDI 
Time (day) 
                                                                                                         Drug Nanosizing Using Microfluidic Reactors       
  
176 
 
 
 
 
 
 
 
 
 
7 Overall Conclusion and Future 
Work
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7.1 Overall conclusion 
 
Nanosizing offers a plausible pharmaceutical approach for improving the 
bioavailability and clinical efficacy of poorly water soluble drugs. In the pharmaceutical 
industry, drug nanosizing is commonly achieved by media milling and homogenization. 
However, these methods have limitations such as processing time and energy 
consumption.  Consequently, efforts are being directed to prepare drug nanosized 
particles with efficient and simpler techniques.  
 
The use of microfluidic reactors for engineering of nanosized particles of organic 
drug molecules has been hypothesized for work in this thesis. For three corticosteroids 
(hydrocortisone, prednisolone and budesonide), the microfluidic nanoprecipitation 
process demonstrated its potential as a promising, straightforward and low energy 
bottom-up preparative technique for drug nanonization.  
 
One of the challenges addressed in this study was an examination of the 
complexity of the microfluidic nanoprecipitation process. For this process, there are 
several interacting variables which can influence the generated drug particle size. 
These factors include microreactor set up (such as internal diameter, angle of fluid 
inlets) and experimental process variables (such as drug saturation level and flow rate 
of inlet streams).  Because of this complexity, an approach using artificial neural 
network software has been employed to model the effect of interacting parameters 
involved in microfluidic nanoprecipitation process. The results of ANNs study revealed 
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that the size of generated drug particles can be directed by modifying microreactors 
set up and changing the processing conditions, notably, the antisolvent flow rate.  
 
Using knowledge generated from the computer based multivariate analysis, the 
microfluidic nanoprecipitation process has been utilised to obtain pharmaceutical 
nanoformulations. Drug nanosuspensions have been prepared by introducing the 
generated nano-sized drug particles into an aqueous solution containing stabilizers. 
However, for the prepared nanosuspension presented in Chapter 4, it was necessary to 
concentrate the drug nanosuspension. This challenge was solved using a tangential 
flow filtration (TFF) system with a membrane of a suitable pore size. This technique for 
concentrating nanosuspension is mild and results presented have shown that it has no 
unwanted effect on drug particles size. At the same time, keeping drug particle size in 
the nano-level is another important requirement in pharmaceutical nanosuspensions 
and their stability. Incorporation of suitable stabilizer(s) system, as demonstrated in 
Chapters 4 and 5, can help manage this issue.  
 
The benefits of the nanosized preparations in drug delivery have been 
demonstrated in Chapters 5 and 6. Particularly demonstrated in Chapter 5, the 
microfluidic prepared hydrocortisone nanosuspension showed a prolonged in vivo 
effect with significant improvement in ocular bioavailability relative to the drug 
solution in rabbits. These advantages are promising when considering the opportunity 
to tailor ocular sustained release formulations to decrease the frequency of 
administration and improve compliance. Nanosizing via microfluidic precipitation was 
also successful in preparing narrow-sized nanosuspensions suitable for pulmonary 
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delivery, as reported for budesonide nanosuspension in Chapter 6.  The in vitro 
aerosolization behaviour of nanosized budesonide was markedly improved in terms of 
MMAD and FPF compared with a commercial suspension formulation.  
 
To conclude, nanoprecipitation within microfluidic reactors demonstrated a 
potential as a promising straightforward and low energy bottom-up technique for drug 
nanonization. However, being a nanoprecipitation method, the following points should 
be considered (Ravichandran 2009): 
 
• The drug needs to be soluble in at least one solvent. Drugs that are 
simultaneously poorly soluble in aqueous and non-aqueous media will 
not be suitable.  
• The solvent should be pharmaceutically acceptable, miscible with the 
nonsolvent and removed easily.   
 
• Preserving size and characteristics of precipitated nanoparticles remains 
a challenge, especially, for the amorphous nanoparticles. 
 
 
7.2 Suggestions for future work 
 
This thesis illustrated the feasibility of engineering drug nanoparticles via 
microfluidic nanoprecipitation. To broaden awareness about this nanosizing technique, 
research can be extended for processing larger number of drugs with different 
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properties. Due to structure limitation, the production capacity of these devices is still 
limited. In the future, approaches needed to address scale-up issues and move beyond 
laboratory rooms and to find a way to industry. Innovations should be developed 
about how to scale up the microfluidic nanonization technique for producing larger 
quantities of nanosized drug products. A simple way of scaling up is by “numbering 
up”, (i.e. arranging many microfluidic reactors in parallel).  
 
In recent reports, a research group at Beijing University of Chemical Technology 
has developed a high-throughput microporous tube-in-tube microchannnel reactor 
(MTMCR) offering a continuous process for production of drug nanoparticles (Wang et 
al. 2009; Zhu et al. 2010) (see Figure 7-1). For consistency and uniformity of product 
from individual microreactors, this approach may prove attractive and cost effective. 
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Figure 7-1: Experimental setup for the preparation of drug nanoparticles in a 
MTMCR.  
 
Schematic diagram of experimental setup: A, drug solution; A′, antisolvent; B, pump; 
C, flowmeter; D, inlet of inner tube; E, inlet of outer tube; F, outlet; G, micropores; H, 
annular microchannel; I, sampling points. (b) Photograph of micropore section. (c) 
Profile of the annular microchannel. 
Source (Zhu et al. 2010). 
 
 
In addition, there are other areas arising from this work which would prove 
useful for further research:   
 
 
• The possibility to produce the generated nanosized drug products in the 
form of solid nanoparticles can be studied. This consecutive step would 
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improve stability of drug nanoparticles. Freeze drying or spray drying 
techniques are suggested. 
 
• The in vitro dissolution behaviour and saturation solubility studies could 
be carried out and compared to the un-nanosized drug particles to 
confirm the theoretical enhancement of these parameters through drug 
nanonization. 
 
• It is also expected that administration of drugs as nanosuspensions will 
enhance drug flux resulting from higher transmembraneous 
concentration gradients (Lenhardt et al. 2008). An in vitro permeability 
study using Caco-2 cells culture could be carried out. 
 
• The enhanced in vitro performance of budesonide nanosized particles 
could be extended by studying the bioavailability of the formulation in 
rats by inhalation of the nebulized colloidal dispersions in a nose-only 
dosing apparatus (Figure 7-2) (Yang et al. 2010). Following exposure to 
the aerosol cloud, serial blood samples can be withdrawn at different 
time intervals and plasma drug level determined using HPLC procedures. 
 
 
                                                                                                         Drug Nanosizing Using Microfluidic Reactors       
  
183 
 
 
 
 
 
Figure 7-2: The nose-only dosing apparatus for rodents. 
   
Source (Yang et al. 2010). 
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Figure 8-1: Picture showing the equipment used in microfluidic precipitation process. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-2: SEM micrograph of unprocessed prednisolone. 
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Figure 8-3: TEM micrograph of microfluidic nanoprecipitated prednisolone particles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-4: TEM micrograph of nanoprecipitated hydrocortisone particles. 
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    Figure 8-5: The Schiotz tonometer. 
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Figure 8-6: TEM micrograph of nanoprecipitated budesonide particles. 
 
 
 
 
 
 
 
Figure 8-7: HPLC standard calibration curve of budesonide. 
 
y = 203.44x + 16.981
R² = 0.9981
0
200
400
600
800
1000
1200
0 1 2 3 4 5 6
Area 
Drug 
concentration 
(ng/ml) 
                                                                                                         Drug Nanosizing Using Microfluidic Reactors       
  
189 
 
 
 
Table 8-I: Effect of experimental parameters on mean particle size of hydrocortisone. 
 
Flow rate 
Channel 
diameter  
          Inlet 
          angle 
Antisolvent: 
solvent 
  (ml/min) 
Mean 
particle 
size 
(nm) 
Antisolvent: 
solvent 
(ml/min) 
Mean 
particle 
size 
(nm) 
Diameter 
(mm) 
Mean 
particle 
size 
(nm) 
Angle 
(°) 
Mean particle 
size 
(nm) 
0.25:0.25 445±24 0.5:0.5 298 ± 15 0.1 N/A 10 230 ± 15 
0.5:0.5 380 ± 19 1:0.5 271 ± 16 0.5 230 ± 15 25 275 ± 20 
1:1 289 ± 31 1.5:0.5 207 ± 21 1 250 ± 18 50 298 ± 17 
1.5:1.5 230 ± 15 2:0.5 152 ± 26     
 
  2.5:0.5 80 ± 19     
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